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Parkinson’s disease (PD) is no longer primarily classified as a motor disorder 
due to the emergence of a number of non-motor symptoms (NMS) of the 
disease. These NMS are highly prevalent and greatly affect the quality of life 
of patients with PD. Thus, an animal model that replicates these symptoms 
is greatly needed to enhance the translational impact of preclinical research. 
The AAV-α-synuclein rat model is the only animal model to date that has 
been shown to robustly and consistently reproduce the primary 
neuropathological and behavioural features of PD. However, there has been 
little research on the ability of the model to replicate NMS of the disease. 
Moreover, this model is most commonly employed unilaterally, which can 
confound cognitive testing due to contralateral functional compensation. 
Thus, the aim of this thesis was to use an AAV2/6 viral vector overexpressing 
human wild-type α-synuclein to characterise NMS of PD, exploring 
behavioural phenotypes of both unilaterally- and bilaterally-administered α-
synuclein. Furthermore, it set out to explore whether voluntary exercise 
could ameliorate motor and NMS in this PD model, including if exercise could 
protect against hippocampal-associated cognitive deficits by modulating 
adult hippocampal neurogenesis.  
We demonstrated that unilateral and bilateral administration of AAV-α-
synuclein induced distinct patterns of nigrostriatal degeneration and 
associated motor dysfunction. Overexpression of AAV-α-synuclein was used 
to model NMS associated with PD, including deficits in hippocampal-
associated tasks. This was coupled with α-synuclein-positive 
immunostaining in the dentate gyrus of the hippocampus, confirming the 
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propagation of the protein throughout distinct regions of the brain. Bilateral 
intranigral administration of AAV-α-synuclein was found to induce motor 
dysfunction and a significant loss of nigral dopaminergic neurons, neither of 
which were rescued by voluntary running. Overexpression of α-synuclein 
also resulted in significant impairment on a neurogenesis-dependent 
pattern separation task, as well as anxiety-like behaviours on both the open 
field and the elevated plus maze. Voluntary running improved performance 
on the pattern separation task only. This was substantiated by an effect on 
hippocampal neurogenesis levels in the dorsal, and not ventral, dentate 
gyrus, suggesting that the functional effects on pattern separation were 





















AAV – adeno-associated virus 
ACC – Anterior cingulate cortex 
ADAGIO - (Attenuation of disease progression with Azilect given once-daily) 
ADL – Activities of daily living 
AHN – Adult hippocampal neurogenesis 
ALS/PDC - Amyotrophic lateral sclerosis-parkinsonism dementia complex 
BBB – Blood brain barrier 
BDNF – Brain-derived neurotrophic factor  
BMP – Bone morphogenetic protein 
BrdU - 3 5-Bromo-2’-deoxyuridine 
BSSG - β-sitosterol β-d-glucoside 
CD - Charles river (sd) 
CED – Convection-enhanced delivery  
CGI – Clinical Global Impression 
CHO – Chinese Hamster Ovary 
CNS – Central nervous system 
COMT - Catechol-O methyl transferase 
COX – Cyclo-oxygenase 
CRT - Choice reaction time 
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CRTT – Choice reaction time task 
CS – Conditioned stimulus 
CSF – Cerebrospinal fluid 
CTA – Conditioned taste aversion 
DA – Dopamine 
DBS – Deep brain stimulation 
DCX – Doublecortin 
DG – Dentate gyrus 
DHA - Docosahexaenoic acid 
dlPFC – Dorso-lateral prefrontal cortex 
E – Embryonic day 
ENS – Enteric nervous system 
EPM - Elevated plus maze 
FGF – Fibroblast growth factor  
FST - Forced swim test 
G – Gram 
GCL – Granule cell layer 
GDF5 – Growth/differentiation factor 5 
GDNF – Glial cell-line derived neurotrophic factor 
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GFAP - Glial fibrillary acidic protein 
GFP – Green fluorescent protein 
GREFEX - Groupe de Réflexion sur l’Evaluation des Fonctions Exécutives 
HMG-CoA - 3-hydroxy-3-methylglutaryl coenzyme A 
ICV – Intracerebroventricular 
IFN – Interferon 
IL – Interleukin 
iNOS - inducible nitric oxide synthase 
L-dopa – levo-dopa 
LE - Long Evans 
LH - Lister Hooded 
LPS – Lipopolysaccharide 
M - Molar 
MCI – Mild cognitive impairment 
Ml - Millilitre 
MFB – Medial forebrain bundle 
Mg - Milligram 
MMSE – Mini-mental state examination 
MPP+ - 1-methyl-4-phenylpyridine 
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MPTP - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSA – Multiple system atrophy 
MWM - Morris water maze 
NAC - Non-amyloid-β component 
NDS – Normal donkey serum 
NGS – Normal goat serum 
NICE - National Institute for Clinical Health and Excellence 
NMDA – N-methyl-D-aspartate 
NMS – Non-motor symptoms  
NOR - Novel object recognition 
NPC – Neural progenitor cell 
NTF – Neurotrophic factor 
NRTN – Neurturin 
OD - Olfactory discrimination 
OF – Open field 
OFC – Orbitofrontal cortex 
OL – Object location 
OR - Object recognition 
PD - Parkinson’s disease 
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PDD – Parkinson’s disease dementia 
PD MCI – Parkinson’s disease with mild cognitive impairment 
PDQ - Parkinson’s disease questionnaire 
PD SURG – PD surgical trial 
PFC – Prefrontal cortex 
PFF – Pre-formed fibril 
PLK – Polo-like kinase 
PPAR - Peroxisome proliferator-activated receptors 
PRET PD - Progressive resistance exercise trial in PD 
RANTES - regulated on activation, normal T-cell expressed and secreted 
RBD – Rapid eye movement sleep behaviour disorder 
REM – Rapid eye movement 
RL – Reversal learning 
RTT - Reaction time task 
ROS – Reactive oxygen species 
SA - Spontaneous alternations 
SD – Sprague Dawley 
SGZ – Subgranular zone 
SIH – Stress-induced hypothermia 
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SN – substantia nigra 
SNCA – α-synuclein gene 
SPT - Sucrose preference test 
SNpc – substantia nigra pars compacta 
SR - Social recognition 
SRTT - Serial reaction time task 
SSRI – Selective serotonin reuptake inhibitors 
SVZ – Subventricular zone 
TCA – Tricyclic antidepressants 
TGFβ -  transforming growth factor β 
TH – tyrosine hydroxylase 
TLR – Toll-like receptor 
TNF-α – Tumour necrosis factor α 
µl – Microlitre 
UPDRS – Unified Parkinson’s disease rating scale 
US – Unconditioned stimulus 
Vg – Viral genomes 
Vl – Ventrolateral 
VM – Ventral mesencephalon 
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VMAT – Vesicular monoamine transporter 
VTA - Ventral tegmental area 
Wt – wild-type 













































Parkinson’s disease (PD) was first reported by James Parkinson in “An essay 
on the shaking palsy” in 1817 (Parkinson, 1817). In it, he described the 
shaking palsy as an “involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; with a propensity to 
bend the trunk forwards, and to pass from a walking to a running pace: the 
senses and intellects being uninjured”, and goes on to detail several patients 
who report a slow but progressive disorder primarily characterised by motor 
dysfunction including hand and arm tremors, akinesia and gait problems.  A 
small number of cases also refer to non-motor symptoms such as 
constipation and speech disruption. Since that initial report, now 200 years 
ago, our knowledge and understanding of PD has been greatly advanced by 
modern science. PD is now described as a degeneration of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) region of the brain, 
and the concomitant loss of the neurotransmitter dopamine (DA) along the 
nigrostriatal pathway leads to the primary motor symptoms associated with 
PD, namely bradykinesia, tremor, rigidity and postural instability. As the 
disease progresses, secondary symptoms manifest themselves as psychiatric 
and cognitive dysfunction, broadly termed “non-motor symptoms” (NMS), 
including depression, dementia and sleep disturbances (reviewed by Cooney 
& Stacy 2016; Todorova et al. 2014). PD is now the second most common 
neurodegenerative disease in the world (Feng et al., 2010). Due to an ageing 
global population, the incidence of PD is on the rise (Savica et al., 2016), and 
is estimated to double in prevalence by 2030 (Dorsey et al., 2007). This 
increases not only the financial and economic impact of the disease 
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(Martinez-Martín et al. 2015; reviewed by Rodriguez-Blazquez et al. 2015) 
but also caregiver burden (Corallo et al., 2016; Grün et al., 2016) and thus 
underlines the importance for continued research into new therapies.  
 
 
3.1 Current treatment of motor symptoms of Parkinson’s 
disease 
 
3.1.1 Pharmacological therapy 
Management of the motor symptoms of PD employs various mechanisms to 
replace the lost DA in the nigro-striatal system. Recommended first line 
therapy involves treatment with either DA agonists such as pramipexole, 
rotigotine or ropinirole which act directly at dopamine receptors, or with the 
amino acid dopamine precursor levo-dopa (L-dopa) (National Institute for 
Clinical Health and Excellence 2006; reviewed by Kakkar & Dahiya 2015) . L-
dopa can be rapidly and extensively converted to dopamine in the periphery, 
so to prevent this it is administered with dopa-decarboxylase inhibitors such 
as carbidopa or benserazide, or may be combined with catechol-O methyl 
transferase (COMT) inhibitors such as entacapone or tolcapone. This not 
only limits side-effects but also ensures that maximal amounts of free L-dopa 
are available to cross the blood brain barrier (BBB) and reach effective 
concentrations in the brain. One of the main issues surrounding L-dopa 
treatment is the eventual emergence of dyskinesias and fluctuations in 
response leading to erratic control of motor symptoms, which can become 
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increasingly problematic for patients (reviewed by Salat & Tolosa 2013). 
Other serious problems associated with prolonged L-dopa therapy include 
the development of compulsive disorders and neuropsychiatric symptoms 
(Voon et al., 2009; Ahlskog, 2011). Duodopa, a new gel infusion of L-dopa 
and carbidopa in combination which can be administered directly into the 
gastro-intestinal system, has been shown to significantly reduce motor 
fluctuations without increasing dyskinesias  (Fernandez et al., 2015; 
Wirdefeldt et al., 2016). However, this preparation is currently only licensed 
for severe, refractory PD (Healthcare and Products Regulatory Agency, 
Summary of Product Characteristics) and the administration involves the 
insertion of a permanent tube via percutaneous endoscopic gastrostomy, 
which can be invasive and confer additional risks onto the patient. National 
Institute for Clinical Health and Excellence (NICE) guidance also outlines the 
use of Amantadine, an N-methyl-D-aspartate (NMDA) receptor antagonist, 
and β-blockers for symptomatic control of motor symptoms but it does not 
recommend these agents as first line therapy (National Institute for Clinical 
Health and Excellence, 2006) 
3.1.2 Surgical therapy 
As the efficacy of L-dopa treatment wanes in some patients, it generally 
becomes necessary to use additional therapies to better control motor 
symptoms. These include surgery such as deep brain stimulation (DBS). DBS 
involves the implantation of an electrode into a suitable brain area, usually 
the subthalamic nucleus or globus pallidus, in an attempt to regulate altered 
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dopaminergic activity that is inherent to PD. Early results from the PD SURG 
trial (PD surgical trial) (Williams et al., 2010) indicate that patients who 
received both DBS and current best medical therapy did significantly better 
in activities of daily living scores and improvements on a PD questionnaire 
(PDQ) scale, a measure of pain disability, than patients who received medical 
therapy alone. However, this coincided with an increased number of adverse 
events that were mostly surgery-related (Williams et al., 2010). There is a 
nine-year follow-up planned for this trial and thus long-term efficacy will be 
addressed in the coming years. There are also reports of DBS alleviating 
some of the non-motor symptoms of PD such as depression or anxiety 
(reviewed by Kim et al. 2015), although the exact mechanisms of these 
effects remain unknown. 
 
3.1.3 Neurotrophic factors as therapy in PD 
 Novel therapeutic strategies in Parkinson’s disease are mainly focused on 
neuroprotection of the existing dopaminergic neurons. Neurotrophic factors 
(NTFs) are known to play a crucial role in the development and maintenance 
of neuronal subtypes, including dopaminergic neurons, and so have been 
extensively researched as a potential therapy for PD (reviewed by Sullivan & 
Toulouse 2011). NTFs from the TGFβ superfamily are the most characterised 
in this respect (reviewed by Hegarty et al. 2014), and include glial cell-line 
derived neurotrophic factor (GDNF), neurturin (NRTN) and 
growth/differentiation factor 5 (GDF5).  Due to promising results from both 
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in vitro and in vivo studies that showed neuroprotective effects (reviewed 
by Bartus et al., 2007 and  Sullivan and Toulouse, 2011), clinical trials in 
humans have been carried out using both GDNF and NRTN. However, issues 
surrounding the poor dissemination of GDNF (Nutt et al., 2003) and NRTN 
(Bartus et al., 2015; Marks et al., 2010) throughout the brain, and the 
development of anti-GDNF antibodies (Lang et al., 2006; Tatarewicz et al., 
2007) have limited progress.  
A unique method of adeno-associated viral (AAV) vector-mediated 
overexpression of GDNF has been shown to achieve, through multiple 
injections and aided by convection-enhanced delivery (CED), the distribution 
necessary to ensure successful and widespread GDNF expression in the brain 
of non-human primates (Richardson et al., 2011). This protocol is currently 
being implemented in a phase 1 clinical trial in patients with advanced stage 
PD in the US (NIH trial NCT01621581).  
 
3.1.4 Cell-based therapies 
Initial proof-of-concept work pioneered chiefly by Anders Bjorklund’s group 
in Lund, Sweden in the 1980s proved that harvesting dopaminergic neurons 
from the developing VM of embryonic rodents and subsequently 
transplanting them into the adult rodent striatum post-neurotoxic lesion 
resulted not only in cell survival and integration, but in restoration of 
dopaminergic neuronal activity and alleviation of motor deficits (Bjorklund 
and Steveni, 1979; Brundin et al., 1987, 1986; Perlow et al., 1979). The 
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results from the first human studies were initially encouraging, with 
significant improvements in motor symptoms, dopamine synthesis and 
storage as well as decreases in the amount of l-dopa  medication required 
by patients (Lindvall et al., 1990, 1989; Sawle et al., 1992; Wenning et al., 
1997; Widner et al., 1992). This led to two large placebo-controlled trials in 
the US, which unfortunately both failed to reach significance in their primary 
endpoints (Freed et al., 2001; Olanow et al., 2003), Interestingly, longer-
term follow up of these patients reported a lasting improvement in UPDRS 
scores at 2 and 4 years post-grafting (Ma et al., 2010), suggesting a delayed 
yet sustained effect. Moreover, very long term data recently published 
supports this theory, with Kefalopoulou et al reporting that two patients, 15- 
and 18 years-post transplant, have remained without dopaminergic 
medication for the last 10 years and display only mild Parkinsonian 
symptoms (Kefalopoulou et al., 2014). Post-mortem analysis of another graft 
patient, 24 years post-transplant, confirmed the long-term viability of the 
transplant (Li et al., 2016). However, due to problems such as the 
development of graft-induced dyskinesias and ethical issues surrounding the 
source of foetal tissue for the transplantations, progress in foetal tissue 
transplantation has largely been halted. Instead, focus has been shifted to 
developing and optimising protocols for the use of stem cell based therapies, 
and readying these therapies for clinical trials, which are the main focuses 
of the newly formed GForce-PD consortium (www.gforce-pd.com).  
Although there are a variety of treatment options currently available to 
patients with PD, the therapies are only aimed at slowing the progression of 
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the disease and none are without caveats. In order to develop robust and 
effective new therapeutic options, more representative models of the 
disease must be used during the screening process to increase the 
translational impact of new drugs. 
 
 
3.2 Non-motor symptoms of PD 
 
Although it was initially thought that PD was primarily a motor disorder, in 
recent years there has been widespread recognition of a broad range of NMS 
that are associated with this disease. In fact, there have been calls to 
reclassify PD as a syndrome rather than a disease to underline the 
importance of recognising PD as a multifaceted condition with a wide variety 
of symptoms that affect both the central and peripheral nervous system 
(reviewed by Titova et al. 2016). Interestingly, it has been shown that some 
of the NMS associated with PD can in fact precede motor symptoms by a 
number of years, termed the prodromal stage of the disease (Pont-Sunyer 
et al., 2015). Constipation has been reported to occur more than 10 years 
prior to motor symptoms, followed by the presence of mood disturbances, 
loss of smell and fatigue that all occur between 2-10 years preceding 
diagnosis (Pont-Sunyer et al., 2015; Postuma et al., 2012). Importantly, it was 
recently shown that some of these NMS can accurately predict cognitive 
decline and survival in PD patients (De Lau et al., 2014; Fullard et al., 2016; 
Shoji et al., 2014), and so a thorough understanding of these NMS is key to 
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better management and outcomes for PD patients (Visanji and Marras, 
2015). 
 
3.2.1 Cognitive impairment and dementia 
Cognitive impairment is common in PD patients, and includes deficits in 
working memory, visuospatial processing, language fluency and verbal 
learning (Siegert et al. 2008; reviewed by Goldman & Postuma 2014). It is 
mostly associated with frontal lobe dysfunction from either cortical atrophy 
(Auning et al., 2014; Green et al., 2002; Pereira et al., 2014; Rektorova et al., 
2014) or Lewy body pathology (Kehagia et al., 2012). The prevalence of 
cognitive impairment ranges widely between studies, between 19 and 36% 
in separate cohorts of early, untreated PD patients (Aarsland et al., 2009; 
Elgh et al., 2009; Foltynie et al., 2004; Muslimovic et al., 2005). This 
variability may be explained in part by differences in tests used to assess 
cognitive functioning, and underlines the difficulty in quantifying cognitive 
deficits. Due to the emerging importance of NMS and their role in predicting 
survival in PD patients, the Movement Disorder Society recently published 
diagnostic criteria for mild cognitive impairment in PD (PD-MCI) (Litvan et 
al., 2012), with a view to standardise diagnoses and highlight patients with 
the potential to progress to PD dementia (PDD). PDD is characterised by a 
broad dysexecutive syndrome,  with profound impairments in visuospatial 
functioning, memory and attention, as well as the development of 
neuropsychiatric symptoms such as hallucinations (Hanagasi et al., 2016). 
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Recent studies employing the new criteria reported a prevalence of PD-MCI 
in approximately 42.5% of patients (Domellöf et al., 2015; Yarnall et al., 
2014). Long-term follow-up data from the initially examined cohorts, (the 
ParkWest study in Norway (Aarsland et al., 2009) and the CamPaiGN study 
in the UK (Foltynie et al., 2004)) have shown that up to 46% of PD patients 
with diagnosed MCI in the initial studies progressed to PDD by 10 years 
(Williams-Gray et al., 2013). The main factors associated with advancing 
from PD to PDD are MCI, specifically semantic fluency and inability to copy 
intersecting pentagon figures, age and severity of motor impairment  
(Pedersen et al., 2013; Williams-Gray et al., 2013, 2009). Other work has 
demonstrated a link between the presence of co-morbid neuropsychiatric 
conditions such as depression or hallucinations and PDD (Wang et al., 2014).  
Interestingly, a proportion of patients initially diagnosed with MCI in the 
ParkWest study (Aarsland et al., 2009) reverted to normal cognition by the 
1-year follow up, suggesting more complex underlying mechanisms. This 
heterogeneous nature of MCI and the differences in PDD progression was 
addressed by Kehagia and colleagues (2012) in their “dual syndrome 
hypothesis”, which states that MCI and PDD are in fact two independent, 
although partially overlapping, syndromes. PD-MCI is characterised by a 
tremor-dominant motor phenotype with deficits in working memory and 
executive function reflective of dysfunctional fronto-striatal circuitry that is 
sensitive to DA therapy. However, PDD is  characterised by a primarily 
akinetic motor phenotype with pronounced gait disturbances and deficits in 
semantic fluency and visuospatial function reflective of posterior cortical 
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and temporal lobe dysfunction which may be ameliorated by cholinergic 
therapy (Kehagia et al., 2012). This theory was further strengthened by a 
study carried out by Nombela (2014), showing that impairments in tasks 
assessing visuospatial,  executive and memory encoding domains were 
associated with region-specific deficits in cortical activity (Nombela et al., 
2014). Since then, a series of papers have further separated PD cohorts into 
5 cognitively differentiated subtypes based on cluster analysis: 1) cognitively 
intact, 2) no cognitive impairment but slight mental slowness, 3) slightly 
impaired overall cognitive ability, 4) severe mental slowing and overall 
cognitive impairment and 5) severe cognitive impairment across all domains 
(Dujardin et al., 2015, 2013). Collectively, the evidence points to a spectrum 
of severity in cognitive impairment in PD patients, which has been shown to 
be far more complex and intricate than initially thought.  
 
3.2.2 Dysexecutive syndrome 
Executive function encompasses all of the mental processes required for 
goal-directed behaviours, including planning, decision making, execution 
and effective performance, and contributes to the ability of a person to be 
useful, socially responsible and constructive throughout life (Lezak, 1982). 
So long as executive functioning remains intact, even people with marked 
cognitive impairment can still maintain their independence and productivity 
(Lezak, 1982). Due to its complexity, measuring executive function is difficult 
and includes a wide variety of tasks measuring outputs such as response 
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inhibition, attentional shifting, cognitive flexibility, rule detection, strategic 
planning and concept formation (reviewed by Jurado & Rosselli 2007). To 
combat this, the Groupe de Réflexion sur l’Evaluation des Fonctions 
Exécutives (GREFEX) published proposed criteria for diagnosing 
dysexecutive syndrome which encompassed both behavioural and cognitive 
domains (Godefroy et al., 2010). These criteria have been recently updated 
and shown to be highly diagnostically accurate (Roussel et al., 2016). 
Executive dysfunction has been well characterised in PD patients (Kudlicka 
et al. 2011; reviewed by Ceravolo et al. 2012), and can affect ADL as simple 
as getting up, dressing, cooking and general multi-tasking (Koerts et al., 
2011). It is thought to be due in part to dysfunctional fronto-striatal circuits 
that connect the basal ganglia to the frontal cortical regions and originate in 
the dorsolateral PFC (dlPFC), the orbitofrontal cortex (OFC) and the anterior 
cingulate cortex (ACC) (Lewis et al., 2012; Zgaljardic et al., 2006). 
Interestingly, recent work has shown that distinct functional-anatomical 
networks within the PFC may be responsible for the processing of different 
forms of executive function, with the dlPFC and ACC largely associated with 
cognitive control and the OFC more related to decision making (Glascher et 
al., 2012).  
 
3.2.3 Neuropsychiatric 
There are a wide variety of neuropsychiatric disturbances that have been 
associated with PD, and importantly they have been shown to be associated 
with disease factors such as motor symptom fluctuations and disease 
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severity and duration (Sagna et al., 2014). PD patients are more likely to 
suffer from depression than age-matched controls, with an estimated 
prevalence of 17% of PD patients suffering from major depressive disorder 
and 35% suffering from clinically significant depressive symptoms (Reijnders 
et al., 2008). A wide variety of factors are thought to contribute to an 
individual’s risk of developing depression, including environmental factors 
(Gallagher and Schrag, 2012), genetic contributions (Collins and Williams-
Gray, 2016) and psychological factors such as the ability to cope with a 
diagnosis of PD (Schrag et al., 2001). Interestingly, Even and Weintraub 
(2012) recently hypothesised that there are three different subtypes of 
comorbid depression in PD patients: patients who would experience 
depression regardless of a PD diagnosis, patients who would be depressed if 
they were diagnosed with another chronic and debilitating illness, and 
patients whose depression is specifically linked to the pathophysiology of PD 
(Even and Weintraub, 2012). This distinction may have important 
implications for the choice of treatment in these patients. Depressive 
symptoms associated with PD are thought to be due in part to dysfunctional 
catecholaminergic and serotonergic neurotransmitter systems (reviewed by 
Aarsland & Gregoric 2015).  Post mortem analysis of brain tissue from PD 
patients has shown widespread deficits in dopaminergic, noradrenergic and 
serotonergic innervation throughout the basal ganglia, cortical and limbic 
regions of the brain (Buddhala et al., 2015), as well as decreased DA and 
noradrenaline transporter binding in the locus coeruleus and throughout the 
limbic system (Remy et al., 2005; Vriend et al., 2013). Moreover, Lewy body 
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pathology has been discovered in brainstem areas that are linked to 
depression including the noradrenergic locus coeruleus (Itoi and Sugimoto, 
2010) and serotonergic raphe nuclei (Lowry et al. 2008; reviewed by 
Gallagher & Schrag 2012).  
Anxiety disorders are also highly common in PD, with some studies 
estimating the prevalence of some form of anxiety at up to 50% (Leentjens 
et al. 2011; Rutten et al. 2015; Pontone et al. 2009). Anxiety disorders 
include generalised anxiety and panic disorder, as well as social anxiety 
(Dissanayaka et al., 2010). Although it was initially thought that anxiety in PD 
is “reactive” as a result of being diagnosed with a chronic and debilitating 
degenerative condition, growing evidence now suggests that it is directly 
related to the pathophysiology of PD (Prediger et al., 2012) and can in fact 
be present for years preceding the onset of motor symptoms (Bower et al., 
2010). Anxiety in PD is frequently associated with depression (Brown et al., 
2011), and as such it is likely that some of their underlying mechanisms 
overlap. Dysfunctional transmission in dopaminergic, serotonergic and 
noradrenergic systems have all been linked to anxiety in PD (reviewed by 
Prediger et al. 2012), however the exact workings remain poorly 
understood.  
It is also estimated that apathy is present in up to 36% of PD patients 
(Pagonabarraga et al., 2015). Although the mechanisms underlying apathy 
in PD remain unclear (Dujardin and Defebvre, 2012), it is thought that 
dysfunction in both the dopaminergic system (Czernecki et al., 2008) and 
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neural circuitry connecting the basal ganglia to the prefrontal cortex (Levy 
and Czernecki, 2006) may play roles.  
 
3.2.4 Autonomic 
Autonomic system deficits, also termed dysautonomia, are well 
characterised in PD and can affect up to 84% of PD patients (Arnao et al., 
2015). These symptoms include orthostatic hypotension (Vichayanrat et al., 
2016), weight loss (Umehara et al., 2016), differences in pain perception 
(Rada et al., 2016) and urinary and sexual dysfunction (Pfeiffer, 2010). 
Notably, they have been shown to markedly impact upon the quality of life 
of patients, significantly affecting ADL, emotional well-being, social support 
and communication and body discomfort  (Tomic et al., 2016).  
 
3.2.5 Olfaction 
Olfactory disturbances are very common and are estimated to affect up to 
70% of PD patients  (Hawkes et al., 1997). The olfactory bulb is thought to 
be the first site of α-synuclein pathology according to the Braak hypothesis 
(Heiko Braak et al., 2003), and smell disturbances have been shown to be 
present years preceding motor symptoms in PD patients (Pont-Sunyer et al., 
2015; Postuma et al., 2012). Interestingly, olfactory deficits appear to be 
specific to PD and could be used to diagnostically discriminate between PD 




Sleep disturbances are very common in patients with PD, and encompass a 
broad range of symptoms including circadian rhythm disturbances, restless 
legs syndrome, rapid eye movement (REM) sleep behaviour disorder (RBD), 
insomnia and excessive daytime sleepiness (reviewed by Chahine et al. 2016; 
Fifel 2016). RBD is defined as a multifaceted parasomnia characterized by 
the loss of atonia that normally occurs during REM sleep, and is associated 
with often violent dream enactment behaviour (Chahine et al., 2016; 
Schenck and Mahowald, 2002). It has recently been shown to be perhaps 
the most sensitive and specific prodromal marker for future development of 
PD (Fereshtenejad et al., 2017). Several longitudinal studies have reported 
that up to 90% of patients with RBD go on to develop either PD or another 
form of synucleinopathy (Boeve et al., 2013; Iranzo et al., 2014). Similarly, 
RBD in PD patients is associated with more severe and debilitating motor 
and NMS (Chahine et al., 2016), and increased α-synuclein deposition 
throughout the brain (Postuma et al., 2015). Although the neuropathology 
of these symptoms is currently poorly understood, any alterations in sleep 
patterns can have drastic effects on quality of life and management of 
symptoms (Prakash et al., 2016). 
 
3.2.7 Gastro-intestinal 
Constipation is the most frequently reported gastro-intestinal symptom of 
PD, affecting up to 63% of PD patients (reviewed by Stirpe et al. 2016). 
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Additionally, other gastro-intestinal disturbances include decreased gastric 
emptying (gastroparesis), malnutrition, dysphagia and small intestinal 
bacterial overgrowth (reviewed by Fasano et al. 2015). It has also been 
shown that PD patients exhibit increased intestinal permeability and 
inflammation when compared to healthy controls (Clairembault et al., 2015, 
2014), and that PD patients have significantly different colonic bacterial 
composition when compared to controls (Keshavarzian et al., 2015).  
Due to the fact that constipation is often present for years preceding the 
onset of motor symptoms in PD patients, there has been a lot of interest 
surrounding the role of the gastro-intestinal system in PD. The idea that the 
initial insult that triggers PD could commence in the gastro-intestinal tract 
was first posited by Braak and colleagues (2003), who outlined potential 
neuronal networks that could be used to transport α-synuclein from the 
enteric to the central nervous system (Braak et al., 2003). Since then, there 
have been numerous reports that support this theory. The vermiform 
appendix has been shown to be rich in α-synuclein (Gray et al., 2014), and 
interestingly an appendectomy may protect against the onset of PD (Mendes 
et al., 2015). Similarly, α-synuclein positive inclusions have been detected in 
the gastric mucosa of PD patients (Sánchez-Ferro et al., 2014), and in the 
gastro-intestinal system up to 8 years prior to the onset of motor symptoms 
(Hilton et al., 2014). Importantly, Holmqvist (2014) injected α-synuclein into 
the gastro-intestinal system of rats, near the myenteric plexus, and 
discovered that the protein was transported via the vagus nerve into the 
dorsal motor nucleus of the brainstem, and so provided the first 
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experimental evidence of α-synuclein propagation from gut to brain 
(Holmqvist et al., 2014). Furthermore, a truncal vagotomy has been shown 
to decrease the risk of PD in human studies, underlining the relevance of the 
vagal nerve to the pathogenesis of the disease (Svensson et al., 2015).  
 
 
3.3 Current treatment of non-motor symptoms of Parkinson’s 
disease 
 
3.3.1 Cognitive impairment, dementia and dysexecutive syndrome 
 
Due to the fact that cortical cholinergic activity is more severely affected in 
PDD compared to Alzheimer’s disease (Bohnen et al., 2003), it stands to 
reason that drugs affecting the cholinergic system such as cholinesterase 
inhibitors would be therapeutically appropriate for treatment of these 
patients. A large systematic review and meta-analysis carried out in 2015 
reported that treatment with cholinesterase inhibitors such as donepezil, 
galantamine and rivastigmine in PDD can significantly improve cognitive 
function, ADL and caregiver burden and are generally well-tolerated (Wang 
et al., 2015). Specifically, rivastigmine is the only currently licensed 
cholinesterase inhibitor for use in PDD (www.bnf.org) and double-blinded 
placebo-controlled clinical trials have shown that it is effective in improving 
general cognitive domains (Schmitt et al. 2010), executive function (Schmitt 
et al. 2010) and ADL (Olin et al., 2010). Memantine, a NMDA receptor 
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antagonist, did not significantly improve cognitive function measured by the 
Mini-Mental State Examination (MMSE) but did increase scores on a Clinical 
Global Impression (CGI) scale (Wang et al., 2015) and has been shown to 
improve executive function in the form of attention, episodic memory and 
goal attainment (Leroi et al., 2014; Wesnes et al., 2015). Despite the 
prevalence of MCI in PD patients and the link between MCI and progression 
to PDD, there is relatively little evidence to inform treatment of MCI in PD 
patients. Interestingly, cholinesterase inhibitors do not seem to be effective 
in MCI, perhaps further supporting the “dual syndrome hypothesis” of two 
independent but partially overlapping syndromes affecting different 
neurotransmitter systems (Kehagia et al., 2012). Galantamine was shown to 
have no effect on memory, executive function or visuospatial performance 
in non-demented patients (Grace et al., 2009). Similarly, treatment with 
rivastigmine resulted in non-significant trends toward improvement of 
cognitive measures (Mamikonyan et al., 2015). Rasagiline, a monoamine 
oxidase B inhibitor, has shown promise in alleviating attention and certain 
executive functions (Hanagasi et al., 2011). Atomoxetine, a selective 
noradrenaline reuptake inhibitor, has been effective in ameliorating 
executive and cognitive dysfunction in PD, although only in small numbers 
of patients (Marsh et al., 2009; Weintraub et al., 2010). A clinical trial 
investigating the effects of piribedil, a dopamine agonist, on motor 
symptoms also carried out a smaller sub-study investigating the effects on 
cognition, and found that piribedil significantly enhanced executive function 




3.3.2 Neuropsychiatric conditions 
3.3.2.1 Depression 
Although depression is a frequent and debilitating co-morbidity in PD, 
antidepressant treatment either through behavioural therapy or 
pharmacological means, has been shown not only to increase quality of life 
(Menza et al., 2009) but also to enhance executive functioning and working 
memory (Dobkin et al., 2014). Despite this, a series of reports and a 
Cochrane review have deemed that there is insufficient evidence either for 
effectiveness or safety of antidepressants for use in treatment of PD (Chung 
et al., 2003; Ghazi-noori et al., 2003; Liu et al., 2013; Miyasaki et al., 2006; 
Price et al., 2011; Skapinakis et al., 2010). Notwithstanding, a recent 
systematic review and meta-analysis concluded that in fact, there is a 
significant effect of the selective serotonin reuptake inhibitor (SSRI) class 
drugs (citalopram, sertraline, fluoxetine and paroxetine) on depression in PD 
patients (Bomasang-Layno et al., 2015). Furthermore, although all the 
clinical trials to date do not provide sufficient power to allow broad 
recommendations, evidence gleaned from smaller trials suggest that 
multiple medications may be beneficial (reviewed by Cooney & Stacy 2016). 
Tricyclic antidepressants (TCA) (amitriptyline, nortriptyline) and serotonin-
noradrenaline reuptake inhibitors (venlafaxine) have shown some degree of 
efficacy in alleviating depressive symptoms in PD patients (Liu et al., 2013; 
Richard et al., 2012). Buproprion, a selective noradrenergic and 
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dopaminergic uptake inhibitor, has been suggested as a suitable treatment 
due to its combined neurotransmitter effects (Raskin and Durst, 2010) and 
has been used to great effect but in very small patient populations (Goetz et 
al., 1984; Załuska and Dyduch, 2011). Pramipexole, a DA agonist used to 
treat motor symptoms of PD, has shown antidepressant effects (Barone et 
al., 2010, 2006; Leentjens et al., 2009). The ADAGIO study (Attenuation of 
disease progression with Azilect given once-daily) was started in 2008 to 
assess the role of rasagiline, a monoamine oxidase B inhibitor as adjunct 
therapy in PD (Olanow et al., 2008). Interestingly, when administered with 
previously initiated antidepressant therapy in trial participants (either a TCA 
or an SSRI), rasagiline improved depressive symptoms when compared to 
placebo (Smith et al., 2015). Importantly, given the proven deficits in several 
brain neurotransmitter systems in depression and PD, it appears logical that 
a drug, or a combination of drugs, that target more than one system may be 
the most applicable in PD patients suffering from these disorders. 
 
3.3.2.2 Anxiety and apathy 
To date, there are no guidelines for the treatment of anxiety in PD patients 
and there have been no clinical trials carried out to address this question 
(Seppi et al., 2011). Treatment of anxiety in patients with PD is the same as 
those without (Akbar and Friedman, 2015; Cooney and Stacy, 2016), with 
more cautious consideration recommended regarding the contribution of 
side-effects to falls risk in PD patients in particular. The situation is similar 
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with treatment of apathy in PD, with limited evidence to adequately inform 
guidelines or recommendations. One small double-blinded placebo-
controlled clinical trial found that transdermal rivastigmine, a cholinesterase 
inhibitor, decreased measures of apathy and increased ADL (Devos et al., 
2014) while a second found that piribedil, a DA agonist, reduced apathy and 
depression scores and improved quality of life (Thobois et al., 2013). 
Methylphenidate, a stimulant that inhibits DA uptake, has also been shown 
to have positive effects on PD patients suffering from apathy (Chatterjee and 
Fahn, 2002; Moreau et al., 2012), though again only in very small patient 
numbers of patients.  
 
3.3.3 Sleep 
In general, clonazepam is the most commonly used therapy for sleep 
disturbances, particularly RBD where it effective in up to 90% of cases (Olson 
et al., 2000; Schenck et al., 2013; Sforza et al., 1997). However, as it is a 
benzodiazepine side effects include excessive daytime sleepiness, which can 
contribute to fall risk in PD patients (Videnovic, 2017) and as such caution 
should be used when prescribing (Aurora et al., 2010). Several small studies 
have also shown that melatonin can be effective in increasing REM sleep, 
either by itself or as an adjunct therapy (Boeve et al., 2003; Kunz and Bes, 
1999; Takeuchi et al., 2001). However, in general there are very limited 
clinical trials for treatment of sleep disturbances specifically in PD patients 
(Amara et al., 2017; Chahine et al., 2016).  
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3.3.4 Autonomic dysfunction 
Postural hypotension can generally be managed in PD patients, depending 
on the severity of symptoms. Non-pharmacological measures include 
increasing water and salt intake and wearing compression stockings (Wu and 
Hohler, 2015). Fludrocortisone, a corticosteroid that increases systemic 
sensitivity to circulating catecholamines is the first-line treatment for 
orthostatic hypotension (Wu and Hohler, 2015). Droxidopa (L-threo-
dihydroxyphenylserine), a synthetic pro-drug that is converted to 
noradrenaline in vivo, has been recently approved for the treatment of 
hypotension in the US and is currently completing phase 3 clinical trials in 
Europe (Wu and Hohler, 2015). Results from earlier trials have shown that 
droxidopa can significantly improve symptoms and standing blood pressure 
measurements as well as decreasing falls (Kaufmann et al., 2015), which is 
of particular importance in PD patients (Hauser et al., 2016).  
 
3.3.5 Gastro-intestinal dysfunction 
Due to the lack of high quality evidence for treatment of gastro-intestinal 
symptoms specific to PD patients, treatment of constipation and associated 
gastro-intestinal dysfunctions are usually the same as in the general 






3.4 Modelling motor and non-motor symptoms of PD 
 
There are currently several experimental animal models of PD in use that 
can be broadly divided into groups based on the method of neuronal 
damage. Dopaminergic neuronal damage can be induced by specific 
neurotoxins, α-synuclein overexpression or by transgenic models. Although 
some of these agents can be administered systemically, most of the models 
require stereotaxic surgery. An advantage of this is that the required 
solution can be injected into the brain unilaterally, allowing the contralateral 
hemisphere of the same animal to act as a control in post mortem tissue 
analysis. Motor impairment can be assessed using a series of lateralised 
tasks including the stepping test (Olsson et al., 1995), the cylinder test 
(Schallert et al., 2000), the corridor test (Dowd et al., 2005) and 
apomorphine- or amphetamine-induced rotations (Ungerstedt and 
Arbuthnott, 1970). However, problems arise when attempting to investigate 
non-motor dysfunction in a unilateral model, as it is well-known that the 
contralateral hemisphere can compensate for the damaged side and thus 
mask any potential deficits. For this reason, bilateral stereotactic injections 
are best used to analyse cognitive function. Motor function in bilateral 
models can be examined using tests such as motor co-ordination and 
sensorimotor integration on the Rotarod apparatus (Rozas et al., 1997), or 





For the purposes of this thesis, all the papers discussed below are on studies 
that used rat models, unless otherwise specified.  
 
3.4.1 The 6-OHDA lesion model 
This model of PD is characterised by injection of the selective 
catecholaminergic neurotoxin 6-OHDA into the midbrain, leading to an 
immediate and profound degeneration of dopaminergic neurons. It has 
been shown to be a reliable and consistent model of PD, reproducing some 
of the main pathological features, namely nigro-striatal dopaminergic 
degeneration, which in turn manifests behaviourally as motor dysfunction 
(Ungerstedt, 1968). 6-OHDA can be administered either into the MFB, the 
striatum or the SN, and administration of the toxin at each of the sites results 
in different behavioural and neuropathological effects (reviewed by Blandini 
et al. 2008). It is generally administered with noradrenergic and serotonergic 
protective agents to ensure that it selectively targets dopaminergic neurons 
(reviewed by Blandini et al. 2008). Although this model has not been shown 
to induce development of α-synuclein-positive inclusions in the brain 
(reviewed by Bové & Perier 2012), it has been used to investigate the NMS 
of PD (see Table 3.1). Bilateral 6-OHDA administration into the rat SN has 
been shown to impair spatial working memory in a Morris water maze 
(MWM) task (Ferro et al., 2005), and has also led to anhedonia and apathy-
like behaviour, measured by decreased sucrose consumption (Santiago et 
al., 2015) in a self-administration operant chamber (Favier et al., 2014) and 
increased time taken to eat 100 sucrose pellets (Pioli et al., 2008), as well as 
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increased immobility time in the forced swim test (FST) (Santiago et al., 
2015). Bilateral striatal administration of 6-OHDA has been more extensively 
characterised and has been shown to induce a wide variety of cognitive and 
emotional impairment, including spatial working memory deficits (Lindner 
et al. 1999; Tadaiesky et al. 2008; Chen et al. 2014; Matheus et al. 2016; 
Betancourt et al. 2016), anxiety and anhedonia-like behaviour (Chen et al., 
2014, 2011; Kumari et al., 2015; Santiago et al., 2015; Silva et al., 2016), 
working memory deficits including social and object recognition (Aidi-Knani 
et al., 2015; Chen et al., 2014; Matheus et al., 2016; Tadaiesky et al., 2008) 
and executive dysfunction in attentional set-shifting and decision making 








































































SNpc or VTA, 
1w between 




































































































































































































































Table 3.1. Summary of the effects of bilateral 6-OHDA lesion on cognitive and 
emotional behaviours. ↑ denotes increased or enhanced performance, - denotes no 
change in performance and ↓ denotes decreased or impaired performance. 
Abbreviations: SD = Sprague Dawley; MWM = Morris water maze; EPM = elevated plus 
maze; FST = forced swim test; Vl = ventrolateral; SR = social recognition; OD = 
olfactory discrimination; SNpc = substantia nigra pars compacta; VTA = ventral 
tegmental area; SA = spontaneous alternations; LE = Long Evans; RL = reversal 
learning; RTT = reaction time task; LH = lister hooded; CD = Charles river (sd); SPT = 
sucrose preference test; OR = object recognition;  CRT = choice reaction time; SRTT = 
serial reaction time task; NOR = novel object recognition 
 
There have also been some reports of cognitive and emotional deficits after 
unilateral intracerebral administration of 6-OHDA (see Table 3.2). A 
unilateral lesion of 6-OHDA into the MFB has been shown to induce anxiety-
like behaviour in the elevated plus maze (EPM) and marble burying tasks 
(Jungnickel et al., 2011; O’Connor et al., 2016) as well as spatial working 
memory deficits in the radial arm maze (Pérez et al., 2009) and the MWM 
(Ma et al., 2014). However, similar papers have shown conflicting evidence 
in both anxiety and cognitive measures (Carvalho et al., 2013), highlighting 
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the variability of using unilateral lesion models to characterise cognitive 
deficits.  
 
3.4.2 The rotenone model 
Rotenone is a naturally occurring toxin commonly used as an insecticide and 
pesticide, and has been used in PD research since the 1980s. Interestingly, 
exposure to pesticides has been linked to increased risk of PD in humans 
(Bellou et al., 2016). The rotenone animal model gained traction when a 
paper published by Betarbet and colleagues (2000) proved that systemic 
administration of rotenone in rats could induce both the pathological and 
behavioural hallmarks of PD, including hypokinesia and rigidity, as well as 
the development of α-synuclein-positive aggregates in nigral neurons 
(Betarbet et al., 2000). Since then, it has also been shown to cause a variety 
of NMS (see Table 3.3). 
Bilateral intra-nigral administration of rotenone in rats has been shown to 
induce deficits in working memory on object recognition tests (Dos Santos 
et al., 2013), loss of olfactory function (Rodrigues et al., 2014) and 
depressive-like behaviour in the FST and sucrose preference test (Santiago 
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Table 3.2. Summary of the effects of unilateral 6-OHDA lesion on cognitive and 
emotional behaviours in rats. ↑ denotes increased or enhanced performance, - 
denotes no change in performance and ↓ denotes decreased or impaired 
performance. Abbreviations: MFB = medial forebrain bundle; CRTT = choice reaction 
time task; MWM = Morris water maze; EPM = elevated plus maze; FST = forced swim 
test; SPT = sucrose preference test; OF = open field; NOR = novel object recognition; OL 
= object location; SD = Sprague-Dawley 
 
 
peritoneal injection or osmotic mini-pump infusion can also cause sleep 
disturbances (García-García et al., 2005; Lax et al., 2012), gastro-intestinal 
dysfunction such as delayed gastric transit and emptying (Drolet et al., 2009; 
Greene et al., 2009), as well as depressive-like behaviour in the FST (Bassani 
et al., 2014; Zaminelli et al., 2014). Although this model displays some of the 
primary behavioural and pathological features of PD, it is not without its 
caveats.  High variability and low reproducibility of lesions as well as high 
mortality rates and systemic toxicity have all limited the use of this model 
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(Cicchetti et al., 2009; Johnson and Bobrovskaya, 2015). Moreover, attempts 
to circumnavigate some of these issues using different administration 
methods such as oral or intranasal delivery in mice and rats have had varied 



















































Table 3.3. Summary of the effects of rotenone administration on cognitive and 
emotional behaviours in rats. ↑ denotes increased or enhanced performance, - 
denotes no change in performance and ↓ denotes decreased or impaired 
performance. Abbreviations: SNpc = substantia nigra pars compacta; FST = forced 










3.4.3 The MPTP model 
This model utilises the metabolism of MPTP in vivo to the neurotoxin MPP+, 
which impairs mitochondrial respiration (Nicklas et al., 1985) and causes 
selective damage to the nigro-striatal system. It thus replicates many of the 
motor deficits seen in PD (reviewed by Bové & Perier 2012). MPTP itself is 
not toxic and can cross the BBB, meaning that it can be administered 
systemically. Some forms of cognitive dysfunction have been characterised 
using the MPTP model (see Table 3.4). Bilateral intra-nigral administration in 
rats has been shown to cause working memory deficits in avoidance tasks 
(Gevaerd et al. 2001; Kumar et al. 2009; Gevaerd et al. 2001b), alternation 
tasks (Braga et al., 2005) as well as social and object recognition (Hsieh et al. 
2012; Huang et al. 2015; Ho et al. 2014). A single intra-nasal dose of MPTP 
has also been shown to induce depressive-like behaviour in the FST and 
working memory deficits in social recognition (Castro et al., 2013). Similar to 
the 6-OHDA model, the MPTP model has not been shown to cause α-
















































































































Table 3.4. Summary of the effects of MPTP administration on cognitive and 
emotional behaviours in rats. ↑ denotes increased or enhanced performance, - 
denotes no change in performance and ↓ denotes decreased or impaired 
performance. Abbreviations: SNpc = substantia nigra pars compacta; MWM = Morris 
water maze; FST = forced swim test; SR = social recognition; SPT = sucrose preference 









3.4.4 The BSSG model 
 A novel and interesting model of PD was recently reported by Van Kampen 
and colleagues (2015). This model utilises a dietary neurotoxin derived from 
the cycad seed, which has previously been linked with Guamanian 
amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS/PDC) 
(Steele and McGeer, 2008). In the report by Van Kampen et al, rats were fed 
a diet containing β-sitosterol β-d-glucoside (BSSG) for 4 months. The animals 
first displayed olfactory deficits, followed by locomotor impairment in the 
form of decreased activity and co-ordination, before finally progressing to 
cognitive dysfunction measured by working memory deficits in both the 
radial arm maze and alternations in the T-maze. This was coupled with 
marked degeneration of TH-positive neurons in the SN and striatal 
innervation by nigro-striatal neurons. Most interestingly, α-synuclein 
positive inclusions were observed, present first in the olfactory bulb and 
then at later time-points throughout the striatum, SN, entorhinal cortex and 
CA1 and dentate gyrus regions of the hippocampus. 
 
3.4.5 Transgenic models 
The vast majority of transgenic rodent models of PD are in mice, and so are 
outside the scope of the purpose of this thesis (Magen and Chesselet, 2010). 
However, there are a small number of transgenic rat 
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lines, fewer still those that have investigated non-motor symptoms of PD. 
Transgenic overexpression of α-synuclein in Sprague-Dawley (SD) rats has 
been shown to induce olfactory dysfunction and α-synuclein-positive 
pathology in the olfactory bulbs (Lelan et al., 2011; Nuber et al., 2013), and 
also to induce an anxiety-like phenotype (Kohl et al., 2016). Interestingly, the 
birth of new neurons in the adult hippocampus, known as hippocampal 
neurogenesis, was severely compromised in these rats, which potentially 
could affect functioning of the hippocampus and associated learning and 
memory, although this was not examined from a behavioural perspective in 
this paper (Kohl et al., 2016).   
 
3.4.6 The α-synuclein model 
 
The α-synuclein model of PD was first described by Kirik et al (2002), when 
an AAV vector was used to overexpress both wild-type and mutated forms 
of human α-synuclein in the dopaminergic neurons of the rat SN. Unilateral 
administration of either vector induced neuronal degeneration in the nigra 
specific to DA neurons and a decrease in striatal DA levels. Animals also 
developed significant unilateral motor impairment in the paw-reaching test 
and apomorphine-induced rotations (Kirik et al., 2002). This paper was the 
first proof-of-concept that α-synuclein overexpression in the midbrain could 
replicate the basic pathological, neurochemical and behavioural features of 
the disease, and established the model as a viable representation of PD. 
Since then, the model has been adapted as various capsid protein serotypes 
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of AAV have been used in order to achieve better transduction of nigral 
dopaminergic neurons, as it is the capsid protein and not the core protein 
that determines the entry method of the virus into the cell. Vectors derived 
from AAV2, 5, 6 and 9 capsid proteins have all been utilised in rats to varying 
success (M Decressac et al., 2012; Mulcahy et al., 2013; Shahaduzzaman et 
al., 2015; Taschenberger et al., 2012). A number of studies have been 
reported  that have used AAV1 core protein-derived vectors (Koprich et al., 
2011, 2010). One of the distinct advantages of this model is the progressive 
nature of the neuronal degeneration and motor dysfunction, which more 
closely replicates the human condition compared to previous models 
(reviewed by Volpicelli-Daley et al. 2016). Surprisingly, given the success of 
the model, relatively little has been characterised with regards to NMS (see 
Table 3.5). Bilateral intra-nigral administration of wild-type α-synuclein has 
been shown to induce depressive-like behaviour in the FST and sucrose 
preference test (SPT) (Caudal et al., 2015), although the same tests 
previously carried out by another group reported no effect of α-synuclein 
(Campos et al., 2013). A novel approach to inducing overexpression of wild-
type α-synuclein in the adult rat forebrain was carried out by injecting the 
AAV vector bilaterally into the striatum of postnatal day 2-4 pups (Aldrin-
Kirk et al., 2014). This group reported that there were no deficits in spatial 
learning in the MWM (Aldrin-Kirk et al., 2014). However, administration of 
wild-type α-synuclein into the  ventral tegmental area (VTA) and medial 
septum/diagonal band of Broca of rats has been shown to induce deficits in 
spatial working memory in the MWM (Hall et al., 2013). Caution should be 
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exercised when interpreting this result in the context of PD as administration 
into this region is not wholly representative of a PD model.   
The so-called “third generation” of the α-synuclein model of PD has been 
developed in very recent years, whereby different forms of α-synuclein such 
as pre-formed fibrils (Paumier et al., 2015), recombinant monomers, 
oligomers and PD lysate taken from human brains (Holmqvist et al., 2014; 
Peelaerts et al., 2015) have all been used to investigate and potentially 
characterise the differential effects of the α-synuclein structure itself on 
motor symptoms. To date, no studies have reported on non-motor 
symptoms using these approaches.  
Although the α-synuclein model is perhaps the most accurate 
representation of the progressive nature of human PD (reviewed by 
Lindgren et al. 2012), it is not without its caveats. The marked variation in 
the serotype of viral vectors and the different forms of the α-synuclein 
protein (wild-type, mutated) that are used by various research groups lead 
to differing neuronal transduction efficiencies, α-synuclein expression and 
behavioural and pathological phenotypes, which makes it difficult to 




































































































Table 3.5. Summary of the effects of α-synuclein overexpression on cognitive and 
emotional behaviours in rats. ↑ denotes increased or enhanced performance, - 
denotes no change in performance and ↓ denotes decreased or impaired 
performance. Abbreviations: SD = Sprague Dawley; wt = wild-type; SN = substantia 
nigra; MWM = Morris water maze; FST = forced swim test; SIH = stress-induced 











3.5 α-synuclein and its role in PD 
 
3.5.1 The SNCA gene and PD 
One of the earliest indications of the link between α-synuclein and PD was 
published by Polymeropolous et al (1997), where a genotype analysis was 
carried out on an Italian family with autosomal dominant inheritance of a PD 
phenotype. They discovered recombination events in the α-synuclein gene 
(SNCA) located on chromosome 4, namely an alanine to threonine 
substitution at position 53 (Ala53Thr, later shortened to A53T), which 
resulted in a shift from α-helix to β-sheet structure of the α-synuclein protein 
(Polymeropoulos et al., 1997). This link was further strengthened later that 
same year with a seminal paper from Spillantini and colleagues (1997), who 
published the first evidence that aggregated α-synuclein was the primary 
constituent of Lewy bodies and Lewy neurites. Since then, various other 
point mutations have been characterised and linked to familial PD, including 
A30P (Krüger et al., 1998) and E46K (Zarranz et al., 2004), as well as both 
duplication (Chartier-Harlin et al., 2004) and triplication (Singleton, 2003) of 
the whole α-synuclein gene. Further mutations that have been discovered 
in recent years include H50Q (Appel-Cresswell et al., 2013; Proukakis et al., 
2013), G51D (Kiely et al., 2013; Lesage et al., 2013) and A53E (Pasanen et al., 
2014). Importantly, the various mutations each appear to result in distinct 
phenotypes of PD, both in vivo (reviewed by Kasten & Klein 2013) and 
experimentally in vitro (Sahay et al. 2015; Lu et al. 2015; Ono et al. 2011; 
Burré et al. 2013).  
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3.5.2 Structure and function of α-synuclein 
α-synuclein is a 140-amino acid protein (14.5kDa) which is encoded by the 
gene SNCA and is highly conserved in vertebrates (Bisaglia et al., 2009). It 
belongs to a small family of synuclein proteins which also includes β-
synuclein and γ-synuclein (Lavedan, 1998). α-synuclein belongs to a class of 
intrinsically unstructured proteins owing to its lack of defined structure in its 
native state (Uversky 2003), and this unique characteristic endows a 
remarkable conformational plasticity which has been shown to be 
dependent on the cellular environment (Bai et al., 2016; Lawand et al., 
2015). In its native form, α-synuclein exists without any stable tertiary 
structure (Eliezer et al., 2001). Upon binding to phospholipid cellular 
membranes, α-synuclein adopts a predominantly α-helical structure 
(Davidson et al., 1998; Eliezer et al., 2001), however it is the misfolding of 
the protein into a β-sheet-rich conformation and the subsequent 
aggregation into insoluble fibrils which form the characteristic Lewy bodies 
and Lewy neurites that are seen in PD.  
Structurally, the native protein is made up of three distinct domains (see 
Figure 3.1): (1) a positively-charged lipid-binding N-terminal region (2) a 
central hydrophobic region known as NAC (for non-amyloid-β component of 
Alzheimer’s disease) and (3) an acidic carboxyl terminus that remains 
unstructured  (Eliezer et al. 2001; Stefanis 2012; Jain et al. 2013; Burré et al. 
2013). Although it was initially thought that the central NAC region was key 
for the formation of α-synuclein aggregates (Lawand et al. 2015; Burré et al. 
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2013; Rodriguez et al. 2015), there is also increasing evidence to support the 
importance of the N-terminus in the aggregation process.  The N-terminus 
has been shown to be critical for α-synuclein membrane interaction and 
permeabilisation (Gaugler et al., 2012; Lorenzen et al., 2014), and all known 
clinical mutations for PD are located on the N-terminus (Dehay et al., 2015). 
A recent study evaluating antibodies against either the N-terminus or central 
region of α-synuclein found that the N-terminus antibody conferred more 
protection against dopaminergic neuronal cell loss and against some 
behavioural deficits compared to the central region antibody 
(Shahaduzzaman et al., 2015). Interestingly, recent work focusing on the role 
of the C-terminus has also shown that this region can modulate the 
aggregation of α-synuclein (Izawa et al., 2012; Izumi et al., 2016; Sahin et al., 
2016). Furthermore, a new compound that targets the C-terminus can 
improve motor deficits and reduce α-synuclein accumulation in several 
transgenic rodent models of PD (Wrasidlo et al., 2016). Taken together, all 
this evidence further consolidates the fact that still, relatively little is known 






Figure 3.1. Schematic depicting the structure of α-synuclein 
 
The endogenous functions of native α-synuclein are yet to be fully 
elucidated. Although this protein is found throughout the body (Böttner et 
al., 2012), it is most highly expressed in the brain. Its localisation at 
presynaptic nerve terminals and its interaction with membrane proteins 
suggest that it plays a role in neurotransmitter release (Bendor et al., 2013). 
Additionally, it has been shown to be involved in facilitating the assembly of 
the SNARE complex (a family of vesicular fusion proteins) (Burré et al., 2010), 
vesicular trafficking (Lee et al., 2011; Nemani et al., 2011), neuronal 
maturation in the dentate gyrus (Winner et al., 2012), DA transmission 
(reviewed by Butler et al. 2016; Buck et al. 2015) and possibly in 
transcriptional regulation in the nucleus, though the latter is still highly 







3.5.3 Post-translational modification of α-synuclein 
α-synuclein can undergo a wide variety of post-translational modifications, 
including N-terminal acetylation (Anderson et al. 2006; reviewed by 
Moriarty et al. 2014), sumoylation (Dorval and Fraser, 2006), ubiquitination 
(Hasegawa et al., 2002; Nonaka et al., 2005), transglutamination (Junn et al., 
2003) and nitration (Barrett & Greenamyre 2015), however it is 
phosphorylation, specifically at serine residue 129 that has been the most 
widely studied with respect to PD (for full review on phosphorylation of α-
synuclein  see Tenreiro et al. 2014; Xu et al. 2015 and Oueslati 2016).  First 
discovered by Fujiwara (2002), s129-phosphorylated α-synuclein is the most 
abundantly expressed protein in Lewy bodies (Anderson et al., 2006). It is 
present under normal conditions in the human brain (Muntané et al., 2012), 
however it is strikingly increased in the brains of patients with PD and other 
synucleinopathies (Fujiwara et al., 2002). Although increased levels of 
phospho-s129 have also been reported in animal models of PD, including the 
6-OHDA lesion model (Ganapathy et al., 2016), the rAAV-α-synuclein 
overexpression model (Aldrin-Kirk et al., 2014) and transgenic mouse 
models (Amschl et al., 2013; Spinelli et al., 2014), the role of phosphorylated 
α-synuclein in the pathogenesis of PD is poorly understood. Some groups 
have reported that phospho-s129 potentiates the toxicity of α-synuclein 
(Gorbatyuk et al., 2008; Sato et al., 2011), and can modulate inclusion 
formation and α-synuclein fibrillation (reviewed by Tenreiro et al. 2014), 
while others argue that there are no differences between the effects of wild 
type and phospho-s129 α-synuclein on nigro-striatal neuronal degeneration 
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or aggregation kinetics (McFarland et al., 2009; Schreurs et al., 2014). Recent 
work by Samuel et al (2015) and Ma et al (2016) suggest that phosphorylated 
α-synuclein may have different effects depending on whether the wild-type 
or mutant protein is present. Interestingly, inducing phosphorylation of 
endogenous α-synuclein through modulation of polo-like kinases (PLKs) 
does not cause nigral dopaminergic neurodegeneration or accumulation of 
phosphor-s129 (Buck et al., 2015). Additionally, phosphorylation at serine 87 
seems to protect against the aggregation of α-synuclein and associated 
toxicities (Oueslati et al., 2012; Paleologou et al., 2010), strengthening the 
argument that the various individual structures of α-synuclein are 
responsible for its distinct effects.  
 
3.5.4 α-synuclein seeding and the aggregation process 
The Braak hypothesis (Braak et al. 2003) describes the pathological staging 
of PD based on the presence of α-synuclein inclusions in certain regions of 
the brain, and theorised that α-synuclein proliferates throughout these 
regions in an ordered and predetermined manner. Starting in the dorsal IX/X 
motor nucleus (and often in the anterior olfactory nucleus), the disease 
pathology ascends rostrally in the brainstem and through susceptible brain 
regions in the midbrain and basal forebrain including subcortical and 
mesocortical regions and olfactory structures, before reaching the 
neocortex (Braak et al. 2003). Each stage of the process correlates with 
increasing severity and type of disease symptoms and clinical manifestations 
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of the disease. Evidence for the movement of α-synuclein throughout the 
brain was further strengthened by the discovery of Lewy body pathology 
within grafted tissue from post mortem analysis of patients who had 
received foetal mesencephalic transplants (Kordower et al. 2008; Kordower 
et al. 2008b). This also suggests that α-synuclein has the ability to travel 
between host and graft tissue (Li et al., 2008). This led to the theory that α-
synuclein can self-propagate throughout the brain in a “prion-like” manner 
(reviewed by Sato et al. 2014 and Recasens & Dehay 2014) via a seeding 
mechanism, whereby exogenous α-synuclein is taken up into neurons via 
endocytosis and induces endogenously expressed α-synuclein to form 
inclusions. These aggregates then cause cell disruption and death, leading to 
the release of more α-synuclein, which is then available for further neuronal 
uptake, so continuing the process. There have been several in vivo and in 
vitro studies published in support of this theory. Sacino and colleagues 
(2013) reported that the addition of exogenous pre-formed fibrils (PFFs) to 
primary mixed neuronal-glial cultures (derived from postnatal day 0 mouse 
brain) was not sufficient to induce endogenous α-synuclein aggregates. 
However, overexpression of human wild-type α-synuclein via an AAV vector 
with the extracellular addition of the PFF “seed” resulted in a rapid and 
marked increase in α-synuclein inclusions primarily formed of endogenous 
α-synuclein. Interestingly, the morphology of the Lewy body was shown to 
be primarily dependent on the structure of the seed applied i.e. wild-type or 
mutant, rather than the type of α-synuclein expressed (Sacino et al., 2013). 
Furthermore, the addition of α-synuclein PFFs to mouse hippocampal 
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primary cultures can accelerate the aggregation of monomeric α-synuclein 
to fibrils (Mahul-Mellier et al., 2015). It has also been shown that injection 
of human recombinant α-synuclein fibrils into the mouse SN induces 
accumulation of endogenous α-synuclein up to 3 months after the fibril 
administration (Masuda-suzukake et al., 2013), as well as propagation of α-
synuclein pathology throughout various interconnected brain regions 
(Masuda-suzukake et al., 2014).  
Broadly, the aggregation process (reviewed in depth by Narkiewicz et al. 
2014) is the transformation of α-synuclein from its native form to a β-rich 
fibrillary structure, which has been shown to be the primary component of 
Lewy bodies (Araki et al., 2015). α-synuclein aggregation begins with the 
formation of intermediary oligomeric structures through the repeated 
addition of monomers (Buell et al., 2014). These oligomers then further 
aggregate, undergoing a series of conformational changes from 
protofilaments to protofibrils before becoming mature α-synuclein fibrils 
(Qin et al., 2007). Although it was initially thought that the mature α-
synuclein fibrils were cytotoxic, growing evidence suggests that oligomers 
may also contribute to cell damage and death (reviewed by Forloni et al. 
2016 and Roberts & Brown 2015) . Oligomeric α-synuclein has been detected 
in post mortem brain tissue from PD patients (Paleologou et al., 2009), and 
has been shown in vitro to disrupt membranes (Perdersen et al., 2015; van 
Rooijen et al., 2010) leading to calcium influx (Danzer et al., 2007) and can 
result in high levels of oxidative stress in neurons (Cremades et al., 2012). 
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There are a wide variety of factors that can influence the aggregation 
process, including the lipid composition (Hellstrand et al., 2013; Tsujimura 
et al., 2015) or pH (Buell et al., 2014) of the cellular environment, the specific 
isoform of α-synuclein that is present (Bungeroth et al., 2014; Lemkau et al., 
2013; Manda et al., 2014; Nielsen et al., 2013), the presence of 
neurotransmitters (Jain and Bhat, 2014; Outeiro et al., 2009; Pham and 
Cappai, 2013) and their respective oxidative states (Fischer and Mansfield, 
2015; Follmer et al., 2015) and post-translational modifications of the 
protein (Kang et al., 2013, 2012; Krumova et al., 2011).  
Importantly, what is evident is that α-synuclein is an incredibly versatile 
protein that can dynamically alter its structure in response to various 
intracellular and extracellular cues. The initial conformation of α-synuclein 
can drastically impact the final structure of the aggregation process (Bai et 
al., 2016; Chen et al., 2015). Growing evidence suggests that different 
structural forms of α-synuclein, or indeed the various post-translational 
modifications that the protein undergoes, may explain the distinct 
pathologies seen within the classes of synucleinopathies (Bousset et al., 
2013; Peelaerts et al., 2015; Prusiner et al., 2015). Peelaerts and colleagues 
extensively characterised behavioural and histopathological effects of 
administration of either α-synuclein ribbons, fibrils or oligomers, and found 
that each structural moiety elicited a different phenotype (Peelaerts et al., 
2015). α-synuclein fibrils proved to be the most neurotoxic, causing 
progressive motor impairment and cell death, whereas administration of α-
synuclein ribbons caused a distinct pattern of phosphorylated α-synuclein 
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accumulation in oligodendroglial cells, more characteristic of multiple 
system atrophy (MSA).  
 
3.5.5 Mechanisms of α-synuclein- induced cell death 
Various mechanisms of α-synuclein-induced cell death have been reported 
(reviewed by Gallegos et al. 2015; Waxman & Giasson 2009; Yasuda et al. 
2013). These include mitochondrial dysfunction (Parihar et al. 2008; Parihar 
et al. 2009; Sarafian et al. 2013; Luth et al. 2014; reviewed by Zaltieri et al. 
2015), endoplasmic reticulum stress (Colla et al., 2012; Gully et al., 2016), 
dysregulation of autophagy (reviewed by Wang et al. 2016), lipid membrane 
disruption (Chaudhary et al., 2014; J. Lee et al., 2012; Mazzulli et al., 2016; 
Pacheco et al., 2015; Reynolds et al., 2011; Rooijen et al., 2010),  pore 
formation (Tosatto et al., 2012) and calcium influx resulting in abnormal 
calcium homeostasis (Danzer et al., 2007; Tosatto et al., 2012; Tsigelny et al., 
2012), as well as oxidative stress and inhibition of microtubule assembly 
(Oikawa et al., 2016; Prots et al., 2013). However, there are two conflicting 
schools of thought on the underlying process of α-synuclein-mediated 
neuronal death. Although it has been widely accepted that dopaminergic 
neurodegeneration inherent to PD is caused by the aggregation of α-
synuclein in Lewy bodies, a so-called gain-of-toxicity function (Oikawa et al., 
2016) more recent work postulates that a loss of endogenous function of 
pre-synaptic α-synuclein through its sequestration into Lewy bodies could 
also be involved (reviewed by Benskey 2016). However, evidence from SNCA 
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knock-out studies does seem to contradict this, as degeneration of 
dopaminergic cell bodies, fibres or synapses do not develop in α-synuclein 
null -/- mice (a homozygous knockout model lacking the SNCA gene), nor do 
these mice display any overt phenotype (Abeliovich et al., 2000). Benskey 
and colleagues argue that this could be as a result of a developmental coping 
mechanism from the SNCA gene knock-out (Benskey et al., 2016). 
Interestingly, SNCA knockdown in adult rats has been shown to reduce 
striatal DA content (Zharikov et al., 2015) and result in marked TH-positive 
cell loss with accompanying motor deficits (Gorbatyuk et al., 2010). 
Additionally, co-expression of endogenous rat α-synuclein with small 
interfering RNAs (siRNAs) selectively targeting endogenous α-synuclein 
partially reversed the PD phenotype in these animals (Gorbatyuk et al., 
2010). Similarly, knockdown of endogenous α-synuclein in non-human 
primates also results in degeneration of dopaminergic neurons (Collier et al., 
2016).  
 
3.6 Inflammation in PD 
 
Growing evidence supports a role for inflammation in the pathogenesis of 
PD (reviewed by Lee et al. 2009). Age is the most common risk factor for 
many neurodegenerative diseases (Ascherio and Schwarzschild, 2016) and is 
accompanied by a chronic low-grade systemic up-regulation of pro-
inflammatory mediators in the absence of overt infection. The term 
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“inflammaging” has been coined to describe this chronic process (Chung et 
al. 2009; Franceschi & Campisi 2014). Importantly, dopaminergic neurons in 
the SN and striatum appear to be particularly vulnerable to inflammatory 
insult (reviewed by Barnum & Tansey 2010), and so neuroinflammation can 
significantly contribute to the pathogenesis of PD (Block and Hong, 2007). Of 
note, head trauma is known to induce an inflammatory reaction in the brain. 
It has been shown to cause progressive nigro-striatal dopaminergic cell loss 
in the rat brain (Hutson et al., 2011), and is linked to higher prevalence of PD 
in humans (Ascherio and Schwarzschild, 2016). Epidemiological evidence for 
a role of inflammation in PD comes from the fact that the regular use of 
several anti-inflammatory medications, including the non-steroidal anti-
inflammatory drug ibuprofen (Chen et al., 2005; Gao et al., 2011) and the 
statin (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors)  class of drugs (Gao et al., 2012) decrease the risk of PD. Similarly, 
peroxisome proliferator-activated receptors (PPARs) are nuclear receptors 
that play an important role in modulating inflammation (Michalik et al., 
2006) and PPAR agonists including pioglitazone and rosiglitazone have been 
shown to exert neuroprotective effects in animals models of PD (Barbiero et 





Figure 3.2. Schematic depicting structural and morphological changes in microglia. Taken from 
Ransohoff (2016).  
3.6.1 Inflammation and aging 
Microglia are the resident innate immune cells of the brain, and are found 
in high concentrations in the SN and striatum (Lawson et al., 1990). Their 
main functions include immune modulation and mediation of innate 
immune responses (Doorn et al., 2012). They can be activated by a number 
of stimuli, including stress, head injury, infections, neuronal damage and 
environmental toxins (reviewed by von Bernhardi et al. 2015), and function 
to clear the cellular environment via phagocytosis of debris from damaged 
or leaky cells (Nimmerjahn et al., 2005; van Rossum and Hanisch, 2004).  In 
most cases, this reaction is self-limiting. However, in some cases, microglia 
can remain chronically activated and continually release a myriad of pro-
inflammatory cytokines and ROS. This chronic activation leads to aberrant 
microglial functioning, as they kill otherwise viable cells, particularly neurons 
(Long-Smith et al., 2009). The resulting cell death triggers further microglial 
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activation, resulting in a vicious cycle of long-lived and self-propelling 
inflammation and oxidative stress known as reactive microgliosis.  
Interestingly, the process of aging is considered to contribute to neuro-
inflammation, and even healthy aged brain tissue displays widespread 
microglial activation throughout various brain regions (Schuitemaker et al., 
2012). However, it remains unclear what drives this increase in upregulated 
microglia. Aging has been shown to cause changes in brain volume and 
cortical thinning, as well as neuronal loss and shrinkage (Anderson et al., 
1983; Sykova et al., 1998; Terry et al., 1987) and microglia may be reacting 
to these profound changes in the microenvironment. Alternatively, it has 
been hypothesised that aging may have a direct impact upon the structure 
of microglia (Conde and Streit, 2006). Morphological changes have 
previously been reported in microglia from aged animal and human studies, 
including cytosolic inclusions, cytoplasmic hypertrophy and other 
ultrastructural abnormalities collectively termed microglial dystrophy 
(Vaughan & Peters 1974; Peinado et al. 1998; Streit et al. 2004, see Figure 
3.2). Given that the ability of microglia to monitor and respond to pathogens 
is dependent on their structural complexity, any structural dysfunction could 
lead to profound functional impairments and subsequently impact on the 
health of the brain. Microglia in aged mice cause significantly more 
dopaminergic neuronal death in an MPTP model of PD and are slower to 
react to acute injury when compared to younger counterparts (Damani et 
al., 2011; Sawada et al., 2007). Recent work has shown that microglia are 
differentially susceptible to aging dependent on their phenotype and 
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location in the brain (Grabert et al., 2016). In addition, several reports have 
shown that there is a possible shift in cytokine balance with aging, as levels 
of pro-inflammatory cytokines such as interleukin (IL)-6 and tumour necrosis 
factor (TNF)-α in the brain increase (Lukiw, 2004; Ye and Johnson, 1999) and 
are accompanied by a subsequent decrease in the levels of anti-
inflammatory cytokine IL-10 in the brain (Ye and Johnson, 2001). Aging is 
accompanied by a cumulative increase in environmental toxins, including 
ROS, in both the body and brain (Chung et al. 2009), and coupled with the 
increased permeability of the BBB also seen in aging (reviewed by Gorlé et 
al. 2016), the brain is left particularly vulnerable to inflammatory insult. The 
shift toward a more pro-inflammatory state and subsequent neuronal 
damage can lead to prolonged microglial activation and contribute further 
to reactive microgliosis. Furthermore, there is growing evidence to support 
the phenomenon of microglial “priming”, namely that chronic exposure to 
inflammation that is consistent with the aging process results in an 
exaggerated response to a second inflammatory stimulus (reviewed by 
Hoeijmakers et al. 2016; Perry & Holmes 2014).  
Taken together, it is clear that the aging process significantly affects both the 
structure and function of microglia. However, whether this dysfunction is as 
a result of chronic over-activation of microglia, or of an inability of microglia 
to complete normal cellular functions is still highly debated (reviewed by 
Harry 2013; von Bernhardi et al. 2015). Given that the main predisposing risk 
factor to developing PD is increasing age (Ascherio and Schwarzschild, 2016), 
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it stands to reason that the age-related changes in microglial functioning 
may play a part in the progression of the disease.  
 
3.6.2 Systemic inflammation in PD 
Several studies have confirmed the link between systemic inflammation and 
PD. Increased levels of cytokines TNF-α, IL-2, IL-6, IFN-γ, IL-1β, the 
chemokine RANTES (regulated on activation, normal T-cell expressed and 
secreted, also known as CCL-5) and markers of oxidative stress have all been 
observed in serum of PD patients compared to age-matched control subjects 
(Andican et al., 2012; Brodacki et al., 2008; Dobbs et al., 1999; Reale et al., 
2009; Rentzos et al., 2009, 2007; Stypula et al., 1996). Serum levels of 
cytokine receptors such as TNF-α receptor 1 are also increased in PD patients 
(Scalzo et al., 2009). Interestingly, growing evidence suggests that peripheral 
inflammatory markers may prove useful tools for not only predicting PD 
(Chen et al., 2008) but also for differentiating between the various subtypes 
of PD (Constantinescu et al., 2010). It has also been shown that levels of 
peripheral cytokines and their receptors in PD patients positively correlate 
with disease progression (measured on the Hoehn-Yahr scale), severity and 
duration (Reale et al., 2009; Tang et al., 2014) as well as with non-motor 
symptoms such as depression  and fatigue (Lindqvist et al., 2012; Menza et 
al., 2010; Pereira et al., 2016; Rocha et al., 2014; X.-M. Wang et al., 2016; 




3.6.3 Central inflammation in PD 
The first evidence that linked neuro-inflammation to the progression of PD 
came from the presence of activated microglia in the SN of post mortem 
brain tissue from PD patients (McGeer et al., 1988). Since then, there has 
been a myriad of data published supporting this association. Increased levels 
of cytokines and cytokine receptors have been detected in the SN of PD 
patients in comparison to controls (Mogi et al., 2000, 2007). Similarly, 
expression of toll-like receptor (TLR) 2, a potent activator of microglia, is 
significantly enhanced in the SN and anterior cingulate cortex of PD patients 
(Doorn et al., 2014; Dzamko et al., 2016). Enzymes associated with 
inflammation, such as inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2), have also been identified post mortem in PD 
brains (Hunot et al., 1996; Knott et al., 2000). Modern imaging studies have 
shown reactive microgliosis in the SN and striatum (Iannaccone et al., 2013) 
as well as the occipital, temporal and parietal cortices of PD patients 
(Gerhard et al., 2006; Terada et al., 2016), highlighting the potential role the 
inflammatory reaction may play in the pathogenesis of NMS in PD.  
 
3.6.4 Supportive evidence from animal models of PD  
Evidence from animal studies further supports the link between neuro-
inflammation and PD. Chronic overexpression of the cytokine IL-1β in the SN 
of rats results in nigral dopaminergic degeneration and motor deficits, as 
well as glial activation (Ferrari et al., 2006). The MPTP model of PD has been 
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shown to cause marked microglial activation in the SN in both mice 
(Czlonkowska et al., 1996) and monkeys (McGeer et al., 2003; Vazquez-
Claverie et al., 2009) as well as increases in levels of pro-inflammatory 
cytokines in the SN of mice (Mandel et al., 2000; Shimoji et al., 2009). Given 
that the 6-OHDA model by its very nature causes cell death through 
oxidative stress (reviewed by Barnum & Tansey 2010), it stands to reason 
that administration of 6-OHDA would also result in a profound inflammatory 
reaction (reviewed by Cebrian et al. 2015), including enhanced microglial 
activation and increased levels of pro-inflammatory cytokines (Cicchetti et 
al., 2002; Marinova-Mutafchieva et al., 2009; Na et al., 2010; Nagatsu and 
Sawada, 2005). Blockade of TNF-α or the TNF receptor has also been shown 
to attenuate nigral dopaminergic cell death in a 6-OHDA rat model (McCoy 
et al., 2006; Mccoy et al., 2008). The rotenone model of PD induces cell 
death at least in part by the formation of ROS, and so will result in a similar 
range of neuro-inflammatory effects (Cicchetti et al., 2009). The use of the 
Gram-negative bacterial endotoxin component LPS as a potent activator of 
microglia has enabled investigations into the precise contributions of various 
inflammatory mediators on the pathogenesis of PD. Administration of LPS 
into the SN activates microglia to release a range of pro-inflammatory 
cytokines and neurotoxic factors such as ROS (Sharma & Nehru 2015 and 
reviewed by Liu & Bing 2011). It selectively damages dopaminergic neurons 
and results in motor deficits similar to those seen in other animal PD models 
(Hoban et al., 2013). Interestingly, administration of LPS in combination with 
α-synuclein overexpression results in enhanced dopaminergic 
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neurodegeneration and motor deficits compared to either LPS or α-
synuclein alone (Mulcahy et al., 2013, 2012). 
 
3.6.5 Inflammation and α-synuclein 
Overexpression of α-synuclein also results in a robust neuro-inflammatory 
reaction. Microglia are activated by the presence of α-synuclein (Alvarez-
Erviti et al., 2011; Codolo et al., 2013; Wilms et al., 2009), releasing a raft of 
pro-inflammatory cytokines and ROS that have been shown to contribute to 
dopaminergic cell death (Wang et al. 2016; Klegeris et al. 2008; Zhang et al. 
2007; Theodore et al. 2008; Chung et al. 2009; Sanchez-Guajardo et al. 2010; 
Cao et al. 2010). Critically, in the context of PD, age-dependent deficits in 
microglial function have been shown to have deleterious effects on the 
ability of microglia to protect against α-synuclein-mediated neurotoxicity 
(Bliederhaeuser et al., 2015). Interestingly, the activation state seems to be 
dependent on the type of protein present (wild-type, mutant) (Hoenen et 
al., 2016) and the aggregation state of the protein (Hoffmann et al., 2016). 
Similarly, microglia isolated from aged animals are unable to efficiently 
phagocytose α-synuclein oligomers in vitro (Bliederhaeuser et al., 2015). 
Furthermore, previous exposure of microglia to α-synuclein results in a 
significantly heightened response to TLR stimulation, so-called microglial 
priming (Roodveldt et al., 2013). A recent paper by Christiansen (2016) 
showed that vaccination against α-synuclein in mice can modulate the 
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microglial population to a more anti-inflammatory phenotype (Christiansen 
et al., 2016).  
 
3.7 Neurogenesis in PD 
 
3.7.1 Neurogenesis 
Neurogenesis is defined as the generation of new neurons from neural 
progenitor cells (NPCs), and it is a key contributor to synaptic plasticity in the 
adult brain (for reviews see Lee et al. 2012; Regensburger et al. 2014; Sailor 
et al. 2017). Neurogenesis has been shown to occur, at least in rodents, 
throughout the lifespan in distinct niches of the brain, namely the 
subgranular zone (SGZ) of the dentate gyrus (DG) and the subventricular 
zone (SVZ) of the lateral ventricles (Altman, 1969; Eriksson et al., 1998). 
Adult neurogenesis has also been shown within the striatum in humans and 
has been suggested to contribute to the generation of new striatal 
interneurons (Eriksson et al., 1998; Gage, 2012; Frisén et al, 2015). While the 
functional significance of new adult striatal neurons is yet to be fully 
understood, it is possible that they contribute to motor and cognitive 
functions such as behavioural flexibility (Ernst and Frisén, 2015). Some of the 
newly born neurons become functionally integrated into neural circuitry 
(Jessberger and Kempermann, 2003; van Praag et al., 2002) , and in the case 
of adult hippocampal neurogenesis (AHN) they are thought to play a key role 
in learning and memory processing and emotional regulation (van Praag et 
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al. 2002; van Praag et al. 2005; Gould et al. 1999; reviewed by Oomen et al. 
2015). Specifically, animal studies in which AHN was ablated have revealed 
that the new-born neurons significantly contribute to spatial memory and 
pattern separation (Clelland et al. 2009; Raber et al. 2004). Pattern 
separation is defined as the process by which overlapping or similar 
representations are transformed into less similar outputs (Sahay et al., 
2011), and it is a process that has been shown to be dependent on AHN 
(Bekinschtein et al., 2014, 2013, 2011; Clelland et al., 2009). Inhibition of 
AHN, either by pharmacological or transgenic methods, increases anxiety-
like behaviours in rodents (Po et al., 2015; Revest et al., 2009). Conversely, 
enhanced neurogenesis can alleviate anxiety and depressive-like behaviours 
(Hill et al., 2015), and many anti-depressant medications have been shown 
to not only increase AHN (Boldrini et al., 2009; Malberg et al., 2000), but to 
be dependent on AHN for their efficacy (Santarelli et al., 2003).  
AHN is sensitive to local and systemic environmental changes. Animal 
studies in mice and macaques have shown that AHN is enhanced by 
environmental enrichment (Kempermann et al., 1997), dietary restriction 
(Lee et al., 2002) and exercise (Farmer et al., 2004; van Praag et al., 1999). 
Conversely, stress (Gould et al., 1998), peripheral inflammation (reviewed 
by Chesnokova et al. 2016) and neuroinflammation (Butovsky et al. 2006; 
reviewed by Sierra et al. 2014; Ryan & Nolan 2016) have all been shown to 
detrimentally affect AHN.  Moreover, blockade of the LPS-induced 
inflammatory reaction using anti-inflammatory medication (Indomethacin, 
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a non-steroidal anti-inflammatory drug) can restore AHN (Monje et al., 
2003).  
Aging also has a profound impact on neurogenesis (reviewed by Lee et al. 
2012). Aged animals show significantly decreased levels of NPC proliferation, 
differentiation and new-born neuron survival (Bondolfi et al. 2004; Kuhn et 
al. 1996; Heine et al. 2004; reviewed by Drapeau & Abrous 2008). Aging 
results in widespread microglial activation and upregulation of pro-
inflammatory cytokines (H. Chung et al., 2009; Schuitemaker et al., 2012), 
which can detrimentally affect AHN (Butovsky et al. 2006; reviewed by Sierra 
et al. 2014; Ryan & Nolan 2016). The functional implications of age-related 
decreases in AHN, and whether it plays a part in age-related deficits in spatial 
memory, are still unclear (reviewed by Drapeau & Abrous 2008). Spatial 
memory impairments in aged animals have been associated with deficits in 
hippocampal circuitry (Bitencourt et al., 2017; Haberman et al., 2017; Rowe 
et al., 2007; Yoo et al., 2016). A study by Driscoll and colleagues positively 
correlated levels of neurogenesis, measured by doublecortin (DCX; a marker 
of immature neurons) and performance on hippocampal-associated 
memory tasks in aged animals, including the MWM, a measure of spatial 
working memory (Driscoll et al., 2006). However, similar studies have not 
been able to replicate this finding (Bizon and Gallagher, 2003; Merrill et al., 
2003).  
One way to address the potential link between age-related deficits in AHN 
and cognitive decline is to delineate the effects of enhancing AHN on 
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hippocampal-assocated learning and memory tasks (reviewed by Ryan & 
Nolan 2016). Animal studies have repeatedly demonstrated that exercise is 
a potent enhancer of AHN, both in young and aged brains (Farmer et al., 
2004; Kronenberg et al., 2006; van Praag et al., 2005, 1999). Importantly, 
exercise has also been shown to improve performance on hippocampal-
associated learning and memory tasks, including pattern separation (Creer 
et al., 2010; Gibbons et al., 2014; Marlatt, 2012; Wu et al., 2015). Although 
this link is by no means causative, it certainly suggests that exercise-induced 
cognitive enhancement in neurodegenerative diseases may be dependent 
on AHN.  
 
3.7.2 Neurogenesis and PD 
Although the majority of work surrounding the link between neurogenesis 
and PD has been focused on neurogenesis in the SVZ (reviewed by 
Regensburger et al. 2014; Le Grand et al. 2015; Lamm et al. 2014), there are 
a few studies linking AHN to the pathogenesis of PD in humans 
(Regensburger et al., 2014). Post mortem brain tissue analysis from PD 
patients revealed decreased NPC proliferation in the SGZ of the 
hippocampus (Hoglinger et al., 2004). Several studies also support the role 
of DA in modularing AHN. For example, DA depletion by a 6-OHDA lesion of 
the nigrostriatal pathway has been shown to impair NPC proliferation in the 
SGZ of rats (Hoglinger et al., 2004). Similarly, MPTP-treated mice exhibited 
decreased DA levels in the hippocampus and decreases in the survival of 
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newly-born neurons in the SGZ (Schlachetzki et al., 2016). The 
mesocorticolimbic DA pathway and dopaminergic projections to the dorsal 
hippocampus have also been shown to be of signicant importance in 
modulating hippocampal-associated learning and memory (Kempadoo et al., 
2016; Wisman et al., 2008).  
Of particular importance in the context of PD is the growing evidence linking 
AHN and α-synuclein (reviewed by Le Grand et al. 2015). α-synuclein has 
been detected in the hippocampus of post mortem PD brain tissue (Flores-
Cuadrado et al., 2016). A pluripotent stem cell line derived from a PD patient 
with a SNCA gene triplication exhibited a marked decrease in NPC 
differentiation when compared to a cell line derived from a healthy control 
subject (Oliveira et al., 2015). Moreover, animal studies have repeatedly 
demonstrated that α-synuclein can decrease hippocampal neuronal 
proliferation and survival both in vitro and in vivo (Crews et al., 2008; 
Desplats et al., 2012; Kohl et al., 2016; Marxreiter et al., 2013; Winner et al., 
2012, 2004). Given that AHN can be detrimentally affected by α-synuclein 
pathology, and that it also may contribute to several NMS which occur in PD, 
it stands to reason that employing neurogenic modulators such as exercise 







3.8 Exercise and PD 
 
Although both motor and NMS of PD are primarily managed using 
pharmaceutical treatments, there is a wealth of evidence to support lifestyle 
interventions such as aerobic exercise having a role to play in 
neuroprotection and symptom management for neurodegenerative 
disorders (reviewed by Paillard et al. 2015 and Inskip et al. 2016). Exercise 
can be defined as a subset of physical activity that is planned, structured, 
repetitive, and purposeful in the sense that improvement or maintenance of 
physical fitness is the objective (Shephard and Balady, 1999). Interestingly, 
exercise has been shown to not only play a role in attenuating symptoms in 
patients with existing PD, but vigorous exercise in mid-life has been shown 
to lead to a reduced incidence of PD in later life (Xu et al., 2010; Ahlskog, 
2011).  
 
3.8.1 Systemic effects of exercise 
Regular exercise can increase cardiovascular endurance and capacity, 
enhance muscular tone, increase muscular strength, improve metabolism, 
and decrease adiposity (reviewed by Bergman 2013; Egan & Zierath 2013; 
Spielman et al. 2016) and is listed as one of the key recommendations for 
cardiovascular disease prevention by the National Institute for Clinical 
Excellence (NICE, www.nice.org.uk). Along with other modifiable lifestyle 
factors such as diet (for e.g. limited salt and fat intake), epidemiological 
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evidence supports the fact that exercise can help reduce the risk of 
cardiovascular disease (Claas and Arnett, 2016), stroke (Niewada and 
Michel, 2016), diabetes (Schrauwen and van Marken Lichtenbelt, 2016) and 
cancer (Lemanne et al., 2013). Exercise has been shown to exert systemic 
anti-inflammatory effects throughout the body, including decreased visceral 
fat mass and increased production and release of anti-inflammatory 
cytokines from skeletal muscle (reviewed by Gleeson et al. 2011). 
Interestingly in the context of inflammation in PD, at least some of these 
effects appear to mediated via TLRs (Zheng et al. 2015; for review see Flynn 
& McFarlin 2006; Gleeson et al. 2006). 
 
3.8.2 Central effects of exercise 
As well as the comprehensive benefits of exercise on systemic health, it can 
also have profound effects on the CNS including enhanced neuroplasticity, 
neurorestoration and neuroprotection (Hirsch et al., 2016; Petzinger et al., 
2013). Exercise increases grey matter volume (Sehm et al., 2014), cortico-
motor excitability (Fisher et al., 2008), striatal DA receptor density and DA 
levels in studies of patients with PD (Fisher et al., 2013). NTFs such as BDNF 
are upregulated from the brain after exercise in human studies (Rasmussen 
et al. 2009; Wagner et al. 2017; reviewed by Dinoff et al. 2016). Exercise 
profoundly enhances hippocampal neurogenesis (reviewed by Ma et al. 
2017) and can improve spatial memory and memory-processing (Vilela et al. 
2016; reviewed by Roig et al. 2013). Exercise has been shown to ameliorate 
82 
 
cognitive deficits seen in CNS disorders such as dementia (reviewed by Groot 
et al. 2016), schizophrenia (reviewed by Vakhrusheva et al. 2016), 
depression (reviewed by Knöchel et al. 2012), Alzheimer’s disease (reviewed 
by Paillard et al. 2015) and PD (reviewed by Murray et al. 2014; Paillard et 
al. 2015; Petzinger et al. 2015).  
 
3.8.3 Exercise in PD 
The first link between exercise and PD, published over 20 years ago, 
reported that exercise during adulthood significantly lowered the risk of 
developing PD in later life (Sasco et al., 1992). This has been confirmed more 
recently in larger scale epidemiological studies (Shih et al., 2016; Yang et al., 
2015). Exercise has also been shown to affect both motor and NMS in 
patients who have already been diagnosed with PD (reviewed by Cusso et al. 
2016 and Dashtipour et al. 2015). A 1h regimen of forced exercise on an 
exercise bicycle can improve UPDRS scores by up to 50% after a single 
session (Alberts et al., 2016). The progressive resistance exercise trial in PD 
study (PRET-PD) was designed to investigate the effects of exercise on both 
motor and non-motor aspects of PD, and reported that structured exercise 
programs enhance both physical function (Prodoehl et al., 2015) and 
cognitive function in the form of attention and working memory (David et 
al., 2015) in PD patients. Exercise has also been shown to improve various 
forms of executive function (Altmann et al., 2016; Cruise et al., 2011; 
Duchesne et al., 2015; Ridgel et al., 2010; Tanaka et al., 2009) as well as 
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olfaction (Rosenfeldt et al., 2016), mood and language fluency in PD patients 
(Altmann et al., 2016; Picelli et al., 2016).  
 
3.8.4 Exercise-induced changes in animal models of PD 
Animal studies have allowed more detailed research into the mechanisms of 
exercise-induced neuroplasticity and neuroprotection. In the context of 
animal models of PD, both the 6-OHDA and MPTP models have been 
extensively investigated using exercise as an intervention. However, due to 
the fact that rats are relatively resistant to the effects of MPTP (reviewed by 
Bové & Perier 2012), all the work carried out to date using this model has 
been in mice. For the purposes of this thesis, I will limit the discussion to 
reports of exercise-induced changes in the pathogenesis of PD in studies that 
used rat models.  
Forced exercise in the form of treadmill running (see table 3.6 for further 
information on type and duration of exercise intervention) either before or 
after unilateral administration of 6-OHDA into the striatum has been shown 
to protect against dopaminergic cell death in the SN (Cho et al., 2013; Choe 
et al., 2012; Real et al., 2013; Yoon et al., 2007), upregulate the expression 
of NTFs in the striatum (Tajiri et al., 2010) and increase the proliferation of 
new neurons in the dentate gyrus (Cho et al., 2013). Exercise was found to 
rescue 6-OHDA-induced motor deficits as measured by rotational behaviour 
and by the cylinder test (Choe et al., 2012; O’Dell et al., 2007; Real et al., 
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2013; Tajiri et al., 2010) and to ameliorate short-term memory deficits in a 
step-down avoidance task (Cho et al., 2013).  
Forced exercise in the form of treadmill running after a unilateral 6-OHDA 
lesion of the MFB protected against striatal dopaminergic cell degeneration 
and restored 6-OHDA-induced deficits in striatal DA levels (Poulton and 
Muir, 2005; Shi et al., 2017; Tillerson et al., 2003). Exposure to either forced 
or voluntary exercise (in the form of access to a running wheel in the home 
cage, see Table 3.7 for further information) in the same model rescued 
motor deficits (Tillerson et al. 2003; Dutra et al. 2012; Hendricks et al. 2012; 
Howells et al. 2005). It has also been shown to normalise the impaired firing 
rates of striatal dopaminergic neurons (Shi et al., 2017) and decrease 6-
OHDA-induced inflammation in the striatum, as measured by glial fibrillary 























Forced treadmill 30m/d 








Forced treadmill 30m 
twice daily for 16d, 





Forced or voluntary wheel 
running, starting 2.5wk 
before lesion and 











Forced treadmill 3/wk, 
starting either 4w before 
lesion for 8 wk or 2d after 
















Forced treadmill for 
30m/d starting 24h post-
lesion 
Rotations ↑ 
Table 3.6. Effects of exercise on the unilateral striatal lesion of 6-OHDA. ↑ denotes 
enhanced or recovered behavioural performance. Abbreviations: SD = Sprague Dawley;  
.  
Interestingly, employing exercise as a neuroprotective rather than 
neurorestorative intervention has had variable results, with some groups 
reporting that exercise had no effect on motor symptoms when animals 
were exposed to either a forced or voluntary exercise regimen prior to a 6-
OHDA lesion of the MFB (Landers et al., 2014, 2013). However, it is worth 
noting that these studies only examined motor behaviours and did not 
investigate the specific neurobiological effects of exercise. This also serves 
to highlight the importance of the timing of the exercise regime when 
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compared to the intervention. To date, no studies have reported on either 
neuroprotective or neurorestorative effects of exercise using the α-















Forced treadmill  
20m twice daily, 6/wk 
for 1 month. Started 














Forced treadmill 15m 
twice daily for 9d, 











Forced treadmill, 5d/wk 
starting 1d before lesion 





Forced treadmill 5/wk, 
starting 3d  





Hendricks  Male SD 
Voluntary access to 
running wheel in 








Forced treadmill for 
5d/wk or voluntary 
wheel running for 6wk 











Forced treadmill for 
5d/wk for 4 wks, either 










Voluntary access to 
running wheel in 
homecage, starting 1wk 
pre-surgery 
Rotations ↑ 
Table 3.7. Effects of exercise on the unilateral MFB lesion of 6-OHDA. ↑ denotes 
enhanced or recovered behavioural performance, - denotes no change in behaviour. 





To summarise, PD is a multifactorial disorder with a broad range of NMS that 
are inherent to the disease process, and are thought to be reflective of α-
synuclein pathology in internconnected brainr regions. However, to date 
there is no PD model that accurately and consistently reproduces these 
important features. Recently, the AAV-α-synuclein rodent model has been 
shown to recapitulate the progressive nature of PD, however the role of α-
synuclein in the development of NMS has yet to be addressed. Thus, the 
hypothesis for this thesis is: 
The propagation of α-synuclein throughout the brain in PD is linked to the 
presence of NMS 
 To test this hypothesis, our aims were: 
a) To identify whether the AAV-α-synuclein model can replicate the 
proliferation of α-synuclein through the brain 
b) To interrogate the link between the presence of α-synuclein throughout the 
brain and the pathogenesis of NMS 
c) To examine whether a neuroprotective intervention such as exercise could 
protect against NMS, specifically hippocampal-associated memory tasks 
d) To investigate if exercise could protect against α-synuclein-induced 






















4.1 Virus preparation 
α-synuclein and GFP plasmids were kindly donated by Dr. Eilis Dowd 
(National University of Ireland, Galway). The viruses were constructed 
(Vector Biosystems Inc, Philadelphia, USA) as described by Decressac et al 
(2012a). Briefly, AAV2 inverted terminal repeats (ITR) coding for either 
human wild type human α-synuclein (figure 4.1A) or GFP (figure 4.1B) were 
packaged using AAV6 capsid proteins to create an AAV2/6 viral vector. 
Transgene expression was driven by a synapsin-1 promoter and enhanced 
using a woodchuck hepatitis virus posttranscriptional regulatory factor 
(WPRE). Viruses were titred by quantitative PCR (qPCR) using the following 
primers:  
Forward    5' tcc ttg tat aaa tcc tgg ttg ctg 3' 
Reverse    5' agc tga cag gtg gtg gca at 3' 
The final viral titres for AAV2/6-αsyn and AAV2/6-GFP were 5.2x1013gc/ml 









Figure 4.1 AAV2 plasmid encoding (A) human wildtype α-synuclein and (B) GFP control 
 
4.2 Solution preparations 
4.2.1 Amphetamine 
A 1mg/ml stock solution of amphetamine was prepared by dissolving 30mg 
D-amphetamine sulphate (Sigma, Ireland) in 30mls sterile water. Animals 
were injected intraperitoneally (i.p.) with a 2.5mg/kg dose. Amphetamine is 
imported, stored and used under licence 5/230-1-2013 issued annually by 




4.2.2 Lithium chloride (LiCl) 
A 0.15M solution of lithium chloride (Sigma, Ireland) was prepared by 
dissolving 3.18g in 500ml of sterile water. Animals received an i.p. dose at 
2% of their bodyweight. This dose is based on previously published literature 
(Inui et al., 2013).  
 
4.2.3 5-Bromo-2’-deoxyuridine (BrdU) 
A 10mg/ml stock solution of BrdU was prepared by dissolving 750mg BrdU 
(Sigma, Ireland) in 75mls sterile water. Animals were injected i.p. with 
75mg/kg in 4 doses, each 2h apart.  
 
4.2.4 Phosphate buffered saline (PBS) 
A solution containing NaCl (162 mM), Na2HPO4 (16.2 mM), Na2H2PO4 (3.8 
mM) (all Sigma, Ireland) was prepared in dH2O and adjusted to a pH of 7.2-
7.4. 
 
4.2.5 Phosphate buffer solution (PB) 
A solution containing NaH2PO4.H2O (0.2M) and Na2HPO4.2H2O (0.2M) was 






4.2.6 Paraformaldehyde (PFA) 
PFA (160 g) (Sigma, Ireland) was dissolved in 1500 ml of distilled H2O (d H2O) 
with continuous stirring on a heated stirrer. Once the solution reached 60-
65°C, 1 M NaOH was added drop-wise until the solution cleared. The solution 
was brought to 2 L with dH2O, diluted 1:1 with 0.2M PBS to give a final 
concentration of 4% and adjusted to pH 7.4 before being cooled to 4°C.  
 
4.3 Animal work 
4.3.1 Animal husbandry 
Rats were maintained on a 12h:12h light: dark cycle (lights on at 08.00h) 
under regulated temperature (21±2°C) and humidity (30-50%). Standard rat 
chow and water were available ad libitum, unless behavioural testing 
dictated otherwise temporarily. Animals were group- housed 2-3 per cage in 
either standard housing conditions or cages with access to custom-designed 
running wheels (Activity Wheel, Tecniplast, UK) unless behavioural testing 
dictated otherwise temporarily. All experiments were conducted in 
accordance with the European Directive 2010/63/EU, and under an 
authorization issued by the Health Products Regulatory Authority Ireland 
(HPRA; AE19130/P010) and approved by the Animal Ethics Committee of 






4.3.2 Stereotaxic surgery 
All surgery for the characterisation study was conducted under general 
anaesthesia induced by an i.p. injection of ketamine and xylazine (80mg/kg 
and 8mg/kg respectively, Zoetis Ireland Ltd and Vetoquinol Ltd, UK) in sterile 
0.9% NaCl. Due to a high mortality rate with injectable anaesthesia and on 
veterinary advice, all surgery in the running study was conducted under 
general anaesthesia induced by inhaled isoflurane (Virbac, Ireland).  
 Animals were placed in a stereotaxic frame (Kopf Instruments) and an 
incision was made through the skin over the skull and the skull was exposed. 
Following the location of bregma and the coordinates of the target injection 
site a drill was used to expose dura. Animals that received a unilateral 
injection were administered with 3µl (3.1 x 108 gc/3µl) of the appropriate 
solution into the right SN at co-ordinates AP -5.3, ML -2.0 and DV -7.2 relative 
to bregma. Animals that received bilateral injections were administered with 
3 µl (1.5 x 108gc/3µl for study 1, 3.1 x 109gc/3µl for study 2) of the 
appropriate solution into each of the left and right SN at co-ordinates AP -
5.3, ML ±2.0 and DV -7.2 relative to bregma. All solutions were infused at a 
rate of 1 µl/min, with an additional two minutes allowed for diffusion before 
the needle was withdrawn. Following injection, the incision was sutured and 
the rats were allowed to recover on a heating mat before returning to their 
home cage. Animals were also administered with the analgesic carprofen 
(Rimadyl® 5mg/kg, s.c., Zoetis Ireland Ltd) and glucose solution (5% in sterile 
saline) immediately following the procedure. Animals that received BrdU 
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injection as a measure of cell survival were administered with 75mg/kg in 4 
doses, each 2h apart one week following surgery.  
 
4.3.3 Tissue processing 
At the appropriate time-points following surgery, animals to be sacrificed for 
immunohistochemistry were deeply anaesthetised with sodium 
pentobarbital (100 mg/kg i.p, Merial Animal Health, UK) and transcardially 
perfused with 100 ml ice-cold heparinised saline (1000IU/l) (Wockhardt, UK) 
followed by 150 ml of 4% paraformaldehyde (pH 7.4). The brains were 
removed and placed into 4% paraformaldehyde overnight for post-fixation 
prior to equilibration in 25% sucrose for a minimum of 48h. Brains were then 
frozen and stored at -80°C before being sectioned on a cryostat (Leica, UK). 
Coronal sections were collected at 40µm thickness in a 1:6 series. For 
analysis other than immunohistochemistry, animals were decapitated, 
brains were removed and the required brain regions were dissected out and 
immediately frozen on dry ice.  
 
4.4 Immunohistochemistry 
Endogenous peroxidase activity was quenched by incubating the tissue in a 
solution of 30% hydrogen peroxide/methanol in distilled water. Non-specific 
secondary antibody binding was blocked using 3% normal goat serum (NGS) 
in a solution of phosphate-buffered saline (PBS) with 0.1% Triton-X 100, 
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adjusted to pH 7.4. Sections were incubated overnight at room temperature 
with appropriate antibody  
(mouse anti-α-synuclein 1:1000, Merck Millipore; mouse anti-TH 1:1000 
Merck Millipore) in 1% NGS in PBS with 0.1% Triton-X 100. The sections were 
then incubated with the appropriate biotinylated secondary antibody (goat 
anti-mouse Vectastain peroxidase ABC kit, Vector, UK at 1:200 dilution) in 
PBS for 3 h, followed by incubation in a streptavidin-biotin horseradish 
peroxidase solution (Vector, UK). Immunoreactivity was visualised by 
incubating the sections with a 0.5% 3,3-diaminobenzidine tetrachloride 
(DAB) solution (containing PBS and hydrogen peroxide 30%) for 5 min. 
Sections were then washed in PBS, mounted on gelatine-coated microscope 
slides, dehydrated in an ascending series of alcohols (50%, 70% and 100%), 
cleared in histolene and cover-slipped using DPX mountant (Sigma, UK).  
 
4.5 Immunofluorescence 
Non-specific secondary antibody binding was blocked using 3% normal 
donkey serum (NDS) in a solution of PBS with 0.3% Triton–X100. Tissue 
sections were incubated overnight (or 48h in the case of doublecortin (DCX)) 
in the appropriate antibody (see Table 4.1) in 1% NDS in PBS with 0.3% Triton 
X-100. Sections were then incubated with the appropriate secondary 
antibodies (see Table 4.2) at 1:200 dilutions in 1% NDS in PBS, and incubated 
with bisbenzamide (1:5000) for nuclear staining, before being coverslipped 
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4.6 Behavioural testing 
4.6.1 Motor testing 
4.6.1.1 Corridor test 
The corridor test of contralateral neglect was carried out as previously 
described (Dowd et al., 2005). Animals were maintained at 90% of their free-
feeding weight for the duration of the test protocol, and were given a small 
number of food rewards in their cages each day.  
On day 1, animals were habituated to the empty apparatus for 5 min. On the 
next day, food rewards (Coco-pops®) were scattered over the floor and 
animals were free to explore and collect the food rewards for 5 min. On day 
3, animals were first placed into an empty corridor for 5 min before being 
moved to the second corridor for 5 min, which had food rewards placed into 
small pots that were located on either side of the corridor. Testing occurred 
on day 4, and animals were placed into an empty corridor for 5 min of 
habituation, before being moved to the “test” corridor where each pot 
contained one food reward.  The test concluded when 5 min had elapsed or 
20 rewards had been taken. Data were expressed as the number of 
contralateral retrievals as a percentage of the total retrievals made.  
 
4.6.1.2 Cylinder test 
The cylinder test was carried out as previously described (Schallert et al., 
2000). Animals were placed in a clear, glass cylinder and the first 20 forepaw 
touches were analysed. The cylinder was cleaned with 70% ethanol between 
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trials. Data were expressed as contralateral touches as a percentage of total 
touches made.  
 
4.6.1.3 Stepping test 
The stepping test of forelimb akinesia was performed as described 
elsewhere (Olsson et al., 1995). Animals were habituated over a number of 
days to being held with both hindlimbs restrained. On days 1 and 2, animals 
were held with both hindlimbs restrained and their backs straight with 
forepaws resting on the countertop. Once the animals were comfortable, 
they were gently moved forward and backward along the counter in a 
“wheelbarrow” type motion. On days 3 and 4 of habituation, both hindlimbs 
and one forelimb were restrained with the remaining free forelimb resting 
on the countertop. Each animal was then moved both forward and backward 
over the countertop while making adjusting steps with the free forelimb, and 
this was repeated until each animal could be held comfortably and reached 
a stable baseline performance.  On the day of testing, both hindlimbs and 
one forelimb were gently restrained, and the animal was held with the 
remaining forelimb placed onto the countertop. The animal was then moved 
sideways across the countertop at a steady pace (90cm in 5s) and the 
numbers of adjusting steps taken with the unrestrained forelimb over both 




4.6.1.4 Rotarod performance 
Animals that had received bilateral injections of viral vectors were tested for 
motor performance using a protocol on the Rotarod apparatus, as described 
elsewhere (Rozas et al., 1997). Briefly, 24h before testing, animals were 
trained on the rotarod until they could remain on the apparatus for 120s 
without falling. On the day of testing, animals were placed on the rotarod 
and tested on the length of time they were able to stay on the apparatus at 
increasing speeds (5-40rpm) for a maximum of 300s was recorded.  
In the second animal study, a more comprehensive Rotarod protocol was 
utilised in order to reduce variability that was seen in the first experiment. 
The protocol (adapted from Marei et al., 2015), consisted of 3 training 
sessions, each containing three trials  of 120s. On day 1, rats were trained at 
5rpm. On day 2, rats were trained in the morning at 10rpm, and in the 
afternoon at 15rpm. Testing took place on day 3, where rats completed 3 
trials of 180s at 15rpm. Latency to fall and frequency of falls in the first 60s 
were measured for all animals. Rats were allowed at least 3min between 
trials to combat stress and fatigue. 
 
4.6.1.5 Open Field test 
Animals were placed in a white, round arena (90cm in diameter) and 
recorded for 10 min.  Motor activity including velocity, distance travelled and 
time spent in the border zone (thigmotaxis) were measured using Ethovision 
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XT software (Noldus Information Technology, Noldus, USA). Apparatus was 
cleaned with 70% ethanol between each test.  
 
4.6.2 Non-motor testing 
4.6.2.1 Olfactory discrimination 
The olfactory discrimination protocol was adapted from Tadaiesky et al 
(2008). Briefly, a cage (45cm long x 28cm wide x 20cm high) was divided into 
two equal compartments with an opening to allow free movement of the 
animal - one side contained each individual animal’s used bedding and the 
other side contained fresh bedding. The animal was put into the fresh 
bedding compartment at the start of the trial. The time spent in each 
compartment was recorded over a period of 5 min. The total number of 
entries into both compartments was also recorded 
4.6.2.2 Spontaneous alternations in the Y maze 
Working memory was measured using spontaneous alternations in a Y maze, 
as described previously (Senechal et al., 2007). The Y maze apparatus was 
black, and consisted of 3 arms, positioned 120° from each other. Each arm 
was 10cm wide, 20cm high and 40cm long (outside length). Briefly, the 
animal was placed in a Y-shaped apparatus for one trial lasting 5 min. The 
animal was placed in the same arm at the beginning of each trial, and 
allowed to freely explore for the duration of the trial. A spontaneous 
alternation was defined as entry into all three arms on consecutive choices. 
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Data were expressed as the percentage of alternation, which was calculated 
by: 
Number of alternations/ (number of entries-2) *100 
4.6.2.3 Conditioned Taste Aversion 
The conditioned taste aversion test was carried out as described previously, 
utilising lithium to induce nausea and malaise in animals to develop a taste 
aversion (Schramm-Sapyta et al., 2011). Prior to testing, animals were given 
a continuous 48 h exposure to two bottles in the home cage, each containing 
either tap water or 0.2% sucrose solution. The starting location of the bottles 
was counterbalanced, and after 24 h, half of the bottles were randomly 
switched to avoid development of a location bias.  
On day 1 of the protocol, animals were water-deprived for 24 h. They were 
then allowed 15 min access to a bottle containing water, and the water 
consumption was measured. Animals were then allowed free access to 
water for 24 h. The next day (day 3), animals were water-deprived again for 
24 h before being allowed 15 min access to a 0.2% sucrose solution. Sucrose 
consumption was measured and the animals were injected with either 0.9% 
NaCl solution or 0.15M LiCl (i.p.) at 2% of their bodyweight (Inui et al., 2013) 
before being allowed free access to drinking water. The next day (day 5), 
animals were again water-deprived for 24 h. On the final day (day 6), animals 
were allowed access to two water bottles for 15min, containing either water 
or sucrose solution and the consumption of each was measured. 
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The percentage preference for the sugar solution was calculated as follows: 
 (sucrose solution consumed mls/ (total water and sucrose solution 
consumed mls) *100 
 
4.6.2.4 Social recognition 
Short-term social memory was assessed using the social recognition 
protocol adapted from Tadaeisky et al (2008). Adult rats were individually 
housed for 3 days prior to testing. On the day of testing, a juvenile rat was 
put in the cage with an adult rat and behaviour was recorded for 5 min. After 
a 30 min interval, the same juvenile rat was put back in the cage with the 
adult rat and behaviour was recorded for 5 min. Adult rats were scored for 
social interaction that included sniffing, touching and grooming of the 
juvenile rat. The discrimination ratio was calculated as: 
Novel Exploration/ (Novel+Familiar Exploration) 
 
4.6.2.5 Discrete alternations in the Y-maze 
Spatial reference memory was assessed using the discrete alternations 
protocol, which was adapted from Deacon & Rawlins (2006) and carried out 
in a Y-maze apparatus (dimensions 10cm high, 20cm wide and 40cm long). 
In order to train the animals to enter the open arm of the maze apparatus 
and retrieve a food pellet, they were first habituated to the apparatus. On 
day 1, each cage of animals was placed into the Y-maze for four 3-min 
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sessions, with all doors open and each arm containing a pot loaded with 
sugar pellets. On day 2, one arm was closed off and each animal was allowed 
to enter from the starting arm to the open arm to collect the food reward, 
with an equal number of left and right entries being completed. When all 
animals freely entered into the open arm to collect the food pellet (generally 
within 3 days) they were deemed trained and ready for the full test protocol. 
On the testing day, after each animal had collected the food pellet from the 
open arm, they were returned to the starting arm. The animal was turned to 
face the wall, and the door to the closed arm was lifted. The animal then 
either chose the “new” arm with a food reward, or the “familiar” arm which 
they had already entered. Correct arm entries were counted and results 
were presented as a percentage of all trials completed. The protocol was run 
again the next day, but to increase cognitive load a 1 min delay was added 
between the animal retrieving the first food pellet in the open arm and 
returning the animal back to the start arm with the closed arm lifted. The 
animal was returned to the home cage for this 1 min interval. The apparatus 








4.6.2.6 Elevated Plus Maze 
Animals were assessed for anxiety-like behaviour using the elevated plus 
maze (Figure 4.2). Each animal was placed in the centre of the apparatus and 
allowed to explore for 5 min. Each trial was recorded and the number of arm 
entries and time spent in open and closed arms were manually scored.  
 
 









4.6.2.7 Modified Spontaneous Location Recognition Task 
Pattern separation was assessed using the spontaneous location recognition 
task, previously described by Bekinschtein et al., (2013). The test was carried 
out in an open field arena (90cm in diameter), covered with bedding under 
dim lighting conditions. The testing room had three proximal cues and distal 
standard furniture. Behaviour was recorded using a camera suspended from 
the ceiling. All bedding was replaced, and the objects and the arena were 
cleaned with 70% ethanol between trials to remove odour cues.  
Animals were habituated to the empty open field arena for 10 min per day 
for 5 consecutive days. After this habituation period, the testing protocol 
began. During the acquisition phase, animals were placed in the arena for 10 
min and allowed to explore three identical objects, placed 15cm from the 
edge of the arena and 30cm from the centre. For the small separation 
paradigm, two of the objects (A2 and A3) were separated by a 50° angle, and 
the third (A1) at an equal distance between the two.  For the large 
separation paradigm, the three objects were separated by 120° angles (see 
figure 4.3).  Glass beer bottles (with labels removed) and soda cans were 
used as objects, and were affixed to the floor with Blu-tac.  Twenty-four 
hours after acquisition, animals were presented with two identical copies of 
the previously-used objects, one (A4) placed in the same position as A1, and 





Figure 4.3. Modified spontaneous location recognition task apparatus set-up (A) and object location 
(B) for small and large separation paradigms. Taken from Bekinschtein et al 2014 and Bekinschtein et 
al 2013. 
 
acquisition locations of A2 and A3. Animals were allowed to explore the 
objects for 5 min. Both objects and locations were counterbalanced across 
all groups. The times each animal spent exploring the object in the novel 
location (A5) and the familiar location (A4) were recorded and a 
discrimination ratio was calculated by: 




4.7 Imaging and image analysis 
Photomicrographs were taken on an Olympus BX53 microscope using 
Cellsens software package. Confocal photomicrographs were taken on an 
Olympus FV1000 confocal laser scanning biological microscope using the 
Olympus FV-10 ASW viewing software package. Images were analysed using 
ImageJ software (ImageJ v.1.51j8, National Institute of Health, USA).  
The fluorescence intensity of TH-positive immunostaining in three coronal 
sections throughout the striatum was measured using ImageJ software. The 
mean pixel intensity was analysed in three fields of view per section and was 
expressed relative to a field through the unstained cortical tissue in each 
section to control for background fluorescence. Fluorescence intensity was 
analysed in the right hemisphere of each animal that received a bilateral 
injection. For animals that received a unilateral injection, the ipsilateral 
hemisphere was expressed as a percentage of the contralateral hemisphere.  
For cell quantification in the SN, cells positive for α-synuclein and TH were 
counted in a 1:6 series. For cell quantification in the dentate gyrus, cells 
positive for BrdU and NeuN were counted in a 1:6 series, and cells positive 
for DCX were counted in a 1:12 series. Dorsal co-ordinates for the dentate 
gyrus were set at -1.8 to -5.2 relative to bregma, and ventral co-ordinates 







4.8 Statistical analysis 
All raw data were analysed using the statistical package Statistica (Statistica, 
US) and graphed using the software GraphPad Prism v5 (GraphPad software, 
US). Data are expressed as means ± the standard error of the mean (SEM). 
Statistical analysis was carried out using a one-way analysis of variance 
(ANOVA) where three or more groups were being compared, repeated 
measures ANOVA where multiple time-points were being compared or 
factorial ANOVA where more than one factor was being analysed.  This was 
followed by a post-hoc Fisher’s LSD test or Dunnett’s test if the ANOVA 
indicated significance. An unpaired Student’s t-test was used where only two 















5.0 Characterisation of neuropathological, motor 
and non-motor symptoms in an α-synuclein rat 













The AAV-α-synuclein rat model is the only animal model to date that has 
been shown to robustly and consistently reproduce the primary 
neuropathological and behavioural features of PD. However, there has been 
little research on the ability of the model to replicate NMS of the disease. 
Moreover, this model is most commonly employed unilaterally, which can 
confound cognitive testing due to contralateral functional compensation. 
Thus, the aims of this study were to investigate differences between the 
effects of unilateral and bilateral administration of AAV-α-synuclein into the 
rat SN, with regards to both motor and NMS of PD. We found that unilateral 
and bilateral administration of AAV-α-synuclein induced distinct patterns of 
nigrostriatal degeneration and associated motor dysfunction. 
Overexpression of AAV-α-synuclein was used to model NMS associated with 
PD, including deficits in hippocampal-associated tasks. This was coupled 
with α-synuclein-positive immunostaining in the dentate gyrus of the 
hippocampus, confirming the propagation of the protein throughout distinct 








For many years, PD was primarily viewed as a motor disorder, however 
growing evidence supports the fact that a wide range of NMS are inherent 
to the disease process. Although there are several experimental animal 
models of PD currently in use, the recent development of the AAV-α-
synuclein overexpression model has been shown to be the most 
representative of the human disease, including replicating the progressive 
nature of the model as well as the formation of α-synuclein aggregates. 
Despite this, relatively little work has focused on the ability of this model to 
reproduce the NMS of PD, or the link between the propagation of α-
synuclein throughout the brain and the presence of NMS. Moreover, the 
majority of the research to date has employed the model as a 
hemiparkinsonian model; namely that the viral vector is administered 
unilaterally, which allows the contralateral hemisphere of the same brain to 
be used as a control in post mortem tissue analyses. Motor impairment is 
then assessed in vivo using well-characterised lateralised tasks including the 
stepping test (Olsson et al., 1995), the cylinder test (Schallert et al., 2000), 
the corridor test (Dowd et al., 2005) and apomorphine- or amphetamine-
induced rotation tests (Ungerstedt and Arbuthnott, 1970). However, given 
that motor dysfunction in humans is generally not evident until 
approximately 30% of dopaminergic neurons in the SN are already damaged 
(reviewed by Burke and O’Malley, 2013), it is clear that significant 
compensatory mechanisms exist that allow for normal movement during the 
early phases of the disease. For example, axonal sprouting after striatal 
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denervation is well-documented in rodent models of PD and has been linked 
with behavioural recovery (reviewed by Arkadir et al., 2014; Zeng et al., 
2012). Similarly, changes in the functional activation of specific brain 
regions, characterised by hypermetabolism on imaging studies, are also 
thought to play a role in compensation (reviewed by Gregory et al., 
2017;Kordys et al., 2017). Moreover, recent work confirms not only the 
presence of cross-hemispheric dopamine projections, but also that these 
can functionally regulate dopamine release in the contralateral hemisphere 
(Fox et al., 2016). Taken together, it is evident that a number of 
compensatory mechanisms exist, and that they can significantly contribute 
to the pathogenesis of the disease. Additionally, it is well established that 
difficulties can arise when assessing cognitive deficits in lateralised models, 
and this is also thought to be due to contralateral compensation.   
 
In light of this, the aims of this chapter are: 
a) To identify whether the AAV-α-synuclein model can replicate the 
proliferation of α-synuclein through the brain 
b) To interrogate the link between the presence of α-synuclein throughout the 
brain and the pathogenesis of NMS 
c) To examine neuropathological and behavioural differences between 
unilaterally- and bilaterally-administered AAV-α-synuclein 
 
To do this, animals received either unilateral or bilateral stereotaxic 
injections of AAV-α-synuclein or AAV-GFP (control) viral vectors. To replicate 
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the progressive and long-term nature of the human disease, animals were 
repeatedly assessed over a period of 40 weeks on a series of motor tasks 
that measured lateralised and bilateral motor dysfunction, as well a number 




5.3 Experimental design 
5.3.1 Animal husbandry 
Adult male Sprague Dawley rats (Envigo, UK) were maintained on a 12h:12h 
light: dark cycle (lights on at 08.00h) under regulated temperature (21±2°C) 
and humidity (30-50%) and pair-housed. Standard rat chow and water were 
available ad libitum, unless behavioural testing dictated otherwise 
temporarily. All experiments were conducted in accordance with the 
European Directive 2010/63/EU, and under an authorisation issued by the 
Health Products Regulatory Authority Ireland (HPRA, AE19130/P010) and 
approved by the Animal Ethics Committee of University College Cork 
(approval number 2013/030). 
5.3.2 Stereotaxic surgery 
All surgery was conducted under general anaesthesia induced by an i.p. 
injection of ketamine and xylazine (80mg/kg and 8mg/kg respectively, Zoetis 
Ireland Ltd and Vetoquinol Ltd, UK) in sterile 0.9% NaCl. Briefly, animals were 
placed in a stereotaxic frame (Kopf Instruments) and an incision was made 
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through to the skull. Animals that received a unilateral injection were 
administered with 3µl (3.1 x 108 gc/3µl) of either AAV-α-synuclein or AAV-
GFP into the right SN at co-ordinates AP -5.3, ML -2.0 and DV -7.2 relative to 
bregma. Animals that received bilateral injections were administered with 3 
µl (1.5 x 108gc/3µl of either AAV-α-synuclein or AAV-GFP into each of the left 
and right SN at co-ordinates AP -5.3, ML ±2.0 and DV -7.2 relative to bregma. 
All solutions were infused at a rate of 1 µl/min, with an additional two 
minutes allowed for diffusion before the needle was withdrawn. Following 
injection, the incisions were sutured and rats were allowed to recover on a 
heating mat before returning to their home cages. Animals were 
administered the analgesic carprofen (Rimadyl® 5mg/kg, s.c., Zoetis Ireland 
Ltd) and 5% glucose solution immediately following the procedure. An 
additional cohort of intact control animals did not undergo surgery. 
 
5.3.3 Experimental design 
Animals were randomly allocated to one of the following experimental 
groups as outlined in Table 5.1: AAV-α-synuclein unilateral, AAV-α-synuclein 
bilateral, AAV-GFP unilateral, AAV-GFP bilateral and intact controls. Motor 
and cognitive tests were carried out over the time-course of the experiment 
as outlined in Figure 5.1, and animals were sacrificed at 20 weeks (Cohort 1) 
or 40 weeks (Cohort 2) post-surgery. Due to significant delays in acquiring 
ethics approval for this animal work, a pilot study was incorporated into the 
experimental design. Cohort 1 consisted of smaller groups as they were used 
115 
 
for non-quantitative analysis of transgene expression. Cohort 2 was 
adequately powered for all behavioural testing and subsequent post mortem 
analysis (n=8-10).  
 Number of animals Number of animals 
Intact Control 4 8 
AAV-GFP bilateral 6 8 
AAV-αsyn bilateral 6 10 
AAV-GFP unilateral 6 8 
AAV-αsyn unilateral 6 10 
   
 Cohort 1 Cohort 2 
Total 28 44 
   








Figure 5.1 Experimental design. Abbreviations: SA = spontaneous alternations; SR = social recognition’ 
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5.3.4 Motor testing 
Given that lateralised tasks are only appropriate in hemiparkinsonian 
models, animals that received unilateral injections were assessed for motor 
dysfunction using the cylinder test, the corridor test, the stepping test and 
the amphetamine-induced rotation test. Animals that received bilateral 
injections were assessed for motor deficits on the rotarod. Tests were 
carried out as described previously (Section 4.6.1). Animals in cohort 1 were 
tested alongside cohort 2 for motor deficits until they were sacrificed at 20 
weeks, and so testing results up to this time-point are cumulative (Cohorts 
1 and 2).  
 
5.3.5 Cognitive testing 
Cognitive functioning was evaluated using conditioned taste aversion, 
olfactory discrimination, spontaneous alternations in the Y-maze and social 
recognition. Animals in cohort 1 were tested (with cohort 2) at the week 20 
time-point before they were sacrificed. Results from weeks 30 and 40 post-
surgery are those from cohort 2 only. All tests were carried out as described 
previously (Section 4.6.2).    
 
5.4 Results 
5.4.1 Administration of α-synuclein had no effect on body weight 
There was no effect of administration of either AAV-α-synuclein or AAV-GFP 
on the body weight of animals in each group (F[4,38] = 1.96, p = 0.11; Figure 
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5.2), although all groups gained weight over the time course of the 
experiment (F[4,152] = 141, p < 0.001).  
 
 
Figure 5.2. Body weights in each of the treatment groups over the course of the experiment. Data are 
expressed as mean ± SEM and analysed using repeated measures ANOVA, ***p<0.001 vs week 0.  
 
Long-term overexpression of unilateral and bilateral AAV-α-synuclein 









5.4.2 Overexpression of α-synuclein into the SN 
Cohort 1 – 20 weeks post-surgery 
Cohort 1 was culled at 20 weeks post-surgery to confirm viral transduction 
and α-synuclein expression. It is important to note that due to low n 
numbers the following data is not quantitative. Animals that received both 
unilateral and bilateral injections of AAV-α-synuclein demonstrated 
considerable α-synuclein expression in the SN (Figure 5.3). In animals 
injected unilaterally, this was accompanied by an apparent decrease in TH-
positive immunostaining in the SN when compared to the intact 
contralateral hemisphere, although this was not quantified (Figure 5.4).  
Cohort 2 – 40 weeks post-surgery 
Immunofluorescent analysis of the number of TH+/α-synuclein+ cells in the 
SN demonstrated that both groups of animals that received AAV-α-synuclein 
displayed approximately 20% transduction of dopaminergic neurons in the 
SN (Figure 5.5A). There was no difference in the number of co-localised 






Figure 5.3 Representative photomicrographs of α-synuclein-positive immunostaining in cohort 1 
animals administered (A) unilateral and (B) bilateral AAV-α-synuclein. Scale bar represents 10 µm. 
 
 
Figure 5.4. Representative photomicrographs of TH-positive immunostaining in cohort 1 animals 
administered with (A) bilateral AAV-GFP, (B) unilateral AAV-GFP, (C) bilateral AAV-α-synuclein and (D) 






In animals that received unilateral AAV-GFP and AAV-α-synuclein, the 
number of TH-positive cells in the SN were expressed as a percentage of 
those in the intact contralateral hemisphere. There was no significant 
difference between groups (F[2,5] = 3.4, p = 0.11). However, a priori analysis 
revealed that overexpression of AAV-α-synuclein resulted in a significant 
reduction of TH-positive cells when compared to the intact control group (p 
= 0.04; Figure 5.5B). In animals that received bilateral AAV-GFP and AAV-α-
synuclein, there was a trend towards a significant reduction in the total 
number of TH-positive cells when compared to controls (F[2,7] = 3.77, p = 
0.07; Figure 5.5C). A priori post hoc analysis revealed that the trend is more 
likely due to an effect of the α-synuclein overexpression (p = 0.07) rather 
than GFP (p = 0.12). 
One-way ANOVA indicated that the extent of TH-positive staining in the 
striatum was significantly different in groups that received unilateral AAV-
GFP and AAV- α-synuclein (F2,63] = 3.55, p = 0.03; Figure 5.5D). Post hoc 
analysis revealed that this was due to differences between control animals 
and AAV-α-synuclein (p = 0.04). Unilateral administration of AAV-GFP 
induced a trend towards a significant reduction in TH-positive 
immunostaining in the striatum (p = 0.052). There was a significant 
difference in the intensity of TH-positive immunostaining in the striatum 
between intact controls and animals that received either bilateral AAV-GFP 
and AAV-α-synuclein (F[2,74] = 7.48, p = 0.001; Figure 5.5E). Post hoc 
analysis revealed a significant decrease in striatal staining intensity in both 
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AAV-GFP (p = 0.002) and AAV-α-synuclein (p = 0.002) groups compared to 
intact controls.   
 
5.4.3 Unilateral intra-nigral administration of AAV-α-synuclein has 
differential effects on contralateral motor function 
In the corridor test of contralateral neglect, overexpression of α-synuclein 
had no effect on the number of contralateral retrievals at any of the time-
points examined (Group F[2,17] = 0.36, p = 0.7, Time [4,68] = 1.31, p = 0.27; 
Figure 5.6A). In the cylinder test of forelimb asymmetry, there were no 
significant differences in the number of contralateral touches between the 
groups (F[2,16] = 0.02, p = 0.97; Figure 5.6B), nor did the performance of the 
groups change over time (F[5,80] = 1.03, p = 0.4). In the stepping test 
measuring forelimb akinesia, there was no overall difference in the number 
of adjusting steps taken between the groups (Group F[2,20] = 1.5, p = 0.23; 
Figure 5.6C). However, the performance of the groups changed significantly 
over time (F[4,80] = 53.61, p = 0.0001). A priori post hoc analysis revealed 
that α-synuclein animals performed significantly worse than intact controls 





Figure 5.5 (A) The percentage transduction efficiency of the AAV viral vector animals administered 
unilateral and bilateral AAV-α-synuclein. TH-positive cell counts in animals administered (B) unilateral 
and (C) bilateral injections. Fluorescence intensity of TH-positive immunostaining in the striatum in (D) 
unilateral and (E) bilateral groups. Representative images of TH-positive cells (F, I), α-synuclein-
positive cells (G,J) and merged images (H,K) in the SN of groups injected with unilateral (F-H) and 
bilateral (I-K) AAV-α-synuclein. Scale bar represents 10µm. Data are expressed as mean ± SEM and 




Figure 5.6 Lateralised motor impairment measured in (A) the corridor test (B) the cylinder test and (C) 
the stepping test. Data are shown as mean ± SEM and analysed using 2-way repeated measures 




Figure 5.7 Latency to fall measured on the rotarod. Data are shown as mean ± SEM and analysed using 




5.4.4 Bilateral intra-nigral administration of AAV- αsynuclein does not affect 
sensorimotor function 
There was no significant difference in the latency to fall off the rotarod 
between groups that had received bilateral injection of AAV-α-synuclein or 
AAV-GFP and the intact controls (F[2,17] = 0.9, p = 0.42; Figure 5.7). All 
groups performed better on the task over the course of the experiment 
(F[5,85] = 9.5, p<0.0001).  
 
5.4.5 Propagation of α-synuclein  
The patterns of AAV-mediated α-synuclein were analysed in distinct brain 
regions for both cohort 1 and cohort 2 (see Table 5.2). Again, it is important 
to note that due to small group sizes in cohort 1, this data is not quantitative. 
Specifically, α-synuclein-positive immunostaining was limited to the SN and 
VTA in cohort 1, which represents 20 weeks of AAV-α-synuclein expression. 
In cohort 2, 40 weeks post-surgery, α-synuclein-positive immunostaining 
was detected in the SN and VTA, as well as the dentate gyrus of the 
hippocampus (Figure 5.8). Interestingly, α-synuclein was expressed in the 
dentate gyrus of both left and right hemispheres, regardless of whether 







SN Hippocampus Amygdala Cortex VTA 
Cohort 1 + - - - + 
Cohort 2 ++ ++ - - + 
Table 5.2 Pattern of α-synuclein expression in distinct brain regions in cohorts 1 and 2. + denotes 




Figure 5.8 Representative photomicrographs of α-synuclein+ immunostaining in (A) the left and (B) the 
right dentate gyrus of unilateral-lesioned animals and (C) the left and (D) the right dentate gyrus of 






Long-term overexpression of AAV-α-synuclein induces distinct changes in 
non-motor behaviours 
 
5.4.6 Spontaneous alternations in the Y-maze 
There was no significant difference in the percentage of spontaneous 
alternations between the groups (F[4,34] = 0.13, p = 0.96; Figure 5.9A). 
However, the percentage of alternations performed by animals in each 
group significantly increased at each time-point over the experiment 
(F[2,68] = 3.98, p = 0.02). The total number of arm entries were also recorded 
for this task. There was no difference in the number of entries made by each 
group (F[4,38] = 2.1, p = 0.08; Figure 5.9B), although there was a significant 
decrease in the total number of entries made by all animals over time from 





Figure 5.9 (A) Percentage of alternations in a spontaneous alternations task. (B)The total number of 
arm entries completed during the task. Data are shown as mean ± SEM and analysed using 2-way 
repeated measures ANOVA and post hoc Fisher’s LSD. ,*p<0.05, ***p<0.001 vs week 20, #p<0.05 vs 








5.4.7 Conditioned Taste Aversion 
Prior to the beginning of this protocol, all animals were given continuous 
access to water and sucrose solution in the home cage. All groups showed a 
clear preference for the sucrose solution (p<0.05; Figure 5.10A). The 
difference in preference for sucrose between lithium- and saline-injected 
animals during the actual test protocol was used as a measure of the degree 
of aversion induced by lithium. Overexpression of AAV-αsynuclein did not 
affect an animal’s ability to successfully develop a lithium-induced taste 
aversion, as animals in all groups, with the exception of those injected 
bilaterally with AAV-GFP, significantly decreased their consumption of 
sucrose in response to a lithium injection when compared to a saline 
injection (p < 0.05; Figure 5.10B). A one-way ANOVA indicated a significant 
difference in the percentage of sucrose consumption by animals in saline-
injected groups (F[4,17] = 5.72, p = 0.004), and post hoc analysis revealed 
that animals that received bilateral AAV-GFP consumed significantly less 
sucrose in the test phase of the paradigm in comparison to intact controls (p 




Figure 5.10 (A) Sucrose and water consumption in all treatment groups. (B) Conditioned taste aversion 
induced by lithium injected measured in all groups. Data are shown as mean ± SEM and analysed using 






5.4.8 Olfactory discrimination 
In the olfactory discrimination test, there was a significant difference in 
discrimination between groups regardless of the time-point (F[4,39] = 4.3, 
p= 0.005; figure 5.11A). Post hoc analysis revealed that the control group 
consistently spent more time exploring the novel compartment compared 
to every other group (Control vs AAV-GFP bilateral, AAV-GFP unilateral p < 
0.01, Control vs AAV-α-synuclein bilateral, AAV-α-synuclein unilateral p < 
0.001). There was a significant change in the performance of the groups at 
over each time-point (F[2,78] = 3.4, p = 0.05), and post hoc analysis revealed 
that all groups spent significantly more time exploring the novel 
compartment from between weeks 30 and 40 (p<0.05). The total number of 
entries into each compartment was also recorded. There was no difference 
in the number of entries made between all of the groups (F[4,35] = 1.1, p = 
0.37; Figure 5.11B), however the number of entries decreased significantly 
over each time-point from week 20 (F[2,70] = 8.4, p = 0.0005). Post hoc 
analysis revealed that the number of entries made by animals in each group 
significant decreased from week 20 to week 30 (p = 0.04) and week 40 




Figure 5.11 (A)The percentage of time spent in the novel odour compartment in an olfactory 
discrimination task. (B) The number of entries into each compartment was recorded for all groups. 
Data are shown as mean ± SEM and analysed using 2-way repeated measures ANOVA and post hoc 
Fisher’s LSD. #p<0.05 vs all other groups, *p<0.05 ***p<0.001 week 30 vs week 40, ~p<0.05 







5.4.9 Social recognition 
There was a significant difference in the ability of each group of animals to 
recognise a juvenile rat that they have previously been exposed to (F[4,39] 
= 5.6, p = 0.001; Figure 5.12). Post hoc analysis revealed that this was due to 
significant impairment in animals from both AAV-GFP unilateral (p = 0.01) 




Figure 5.11 A) Discrimination ratio from a social recognition task. Data are expressed as mean ± SEM 











The AAV-α-synuclein model is one of the few animal models of PD that can 
reproduce the pathological hallmark of the disease; α-synuclein-positive 
inclusions termed Lewy bodies. Although the model has been well-
characterised in terms of neurochemical and neurobiological effects, as well 
as motor behaviours (Decressac et al., 2012), to date relatively little research 
has focused on the potential for this model to replicate NMS associated with 
PD. Moreover, the majority of the studies have employed unilaterally 
administered AAV-α-synuclein, which enables the contralateral hemisphere 
to act as a control in post mortem analyses. However, given that significant 
compensatory mechanisms exist, including the recent discovery of cross-
hemispheric dopaminergic projections that can modulate dopamine 
transmission in the contralateral hemisphere (Fox et al., 2016), it is unclear 
what role these mechanisms may play in unilateral-lesion models. To our 
knowledge, to date there has been no study published that employed 
bilateral AAV- α-synuclein as a viable model of PD. Thus, the aims of this 
study were to employ the AAV-α-synuclein model to compare the 
neuropathological and behavioural effects induced by both unilateral and 
bilateral administration into the rat SN. Moreover, we investigated if long-
term overexpression of both unilateral and bilateral AAV-α-synuclein could 
replicate a variety of NMS that are associated with PD.  
To date, most of the published work using the AAV-α-synuclein model has 
also employed an AAV-GFP vector as a control. This doubles as both a control 
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for surgery and as a control for the expression of the AAV viral vector. 
However, the majority of these studies are designed to examine the acute 
effects of α-synuclein overexpression, and as such these experiments are 
typically no longer than 12-16 weeks in duration (Decressac et al., 2012; 
Lundblad et al., 2012; Mulcahy et al., 2013). The present study was designed 
to specifically investigate whether long-term overexpression of α-synuclein 
leads to propagation of the protein throughout the brain resulting in 
associated NMS, and so both AAV-α-synuclein and AAV-GFP were 
overexpressed in the SN for over 40 weeks. In reviewing the data from this 
chapter, a recurring concern that arose was the behavioural and 
pathological data from the animals that received the control AAV-GFP viral 
vector. Unilateral administration of AAV-GFP into the SN led to a marked 
decrease in the number of TH-positive neurons, while bilateral 
administration led to reductions in both the number of dopaminergic 
neurons and the intensity of striatal TH-positive immunostaining, at levels 
comparable to animals injected with AAV-α-synuclein. Similarly, the 
performance of animals that received AAV-GFP was worse than animals in 
the intact control group, both in the social recognition and the conditioned 
taste aversion tasks. Although the use of GFP as a viral vector control is well-
established in in vivo studies, a comprehensive overview of the literature 
demonstrates that, in fact, the effects of AAV-GFP are highly variable. AAV-
GFP overexpression has been shown to result in non-significant decreases in 
dopaminergic neurons in the SN of between 10 and 20% of that of the intact 
contralateral side (Decressac et al., 2012; Gombash et al., 2013; Gorbatyuk 
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et al., 2010; Kirik et al., 2003), as well as non-significant reductions in striatal 
TH-positive fibre density of up to 30% (Taschenberger et al., 2012) and non-
significant effects on vesicular monoamine transporter (VMAT, a marker of 
dopamine transport)-positive neurons in the SN of 20% (Gaugler et al., 
2012). Furthermore, overexpression of AAV-GFP has also been shown to 
increase the number of CD68+ and MHCII+ cells, both indicative of microglial 
activation (Sanchez-Guajardo et al., 2010). Despite these worrying trends, 
AAV-α-synuclein groups in these studies are only being compared to AAV-
GFP and so any GFP-induced effects are not being adequately controlled for. 
An elegant study by Koprich and colleagues (2010) compared the AAV-α-
synuclein and AAV-GFP vectors to an empty AAV vector, and reported that 
GFP resulted in a significant 37% reduction in TH-positive neurons in the SN 
(Koprich et al., 2010). Moreover, a recently published review article 
addresses concerns surrounding the use of GFP as a control in both in vitro 
and in vivo studies, and lists possible mechanisms by which GFP causes cell 
toxicity and immunogenicity (reviewed by Ansari et al., 2016). These include 
increased free radical oxygenation, activation of apoptotic pathways and 
enhanced cell permeability leading to cell death (Ansari et al., 2016). Despite 
this, the use of AAV-GFP remains the gold-standard for viral vector control 
in this field of research. However, for the purposes of this chapter, where 
possible we will directly compare AAV-α-synuclein to intact control animals 
to negate the possible toxicity of the AAV-GFP groups.  
Moreover, based on the findings from this chapter, we planned an additional 
experiment to delineate both acute and long-term specific AAV-GFP effects 
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from that of intact control animals as well as animals injected with sterile 
0.9% NaCl. Unfortunately, due to problems with the relocation of the animal 
facility in UCC, animals had to be sacrificed before the expected end of the 
experiment. Nevertheless, in the subsequent chapter of this thesis, sterile 
0.9% NaCl will be used a control instead of AAV-GFP.   
Leaving aside the problems surrounding the AAV-GFP vector, in this chapter 
we show that both unilateral and bilateral administration of AAV-α-
synuclein resulted in the transduction of approximately 20% of 
dopaminergic neurons, and that both paradigms induce distinct patterns of 
nigrostriatal degeneration, and that the propagation of α-synuclein 
throughout the brain appears to be at least partially dependent on the 
duration of expression. Interestingly, there was no difference in the 
percentage of TH-positive cells transduced with the viral vector between 
animals that received either unilateral or bilateral injections, despite the 
difference in doses of vector administered. Unilateral administration of AAV-
α-synuclein induced a significant reduction in the number of dopaminergic 
neurons in the SN and a significant, albeit moderate, decrease in the 
intensity of TH-positive immunostaining in the striatum. However, bilateral 
administration of the same vector resulted in a far more robust effect, 
inducing the loss of approximately 40% of nigral dopaminergic neurons as 
well as a more profound effect on striatal TH-positive immunostaining. 
Previously published studies using a similar unilaterally-administered 
AAV2/6 viral vector reported a reduction of approximately 80% in the 
number of TH-positive neurons in the SN and 60% decrease in the density of 
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striatal fibres (Decressac et al., 2012), and although in this study we used the 
same dose of vector we were unable to replicate the extent of nigrostriatal 
degeneration previously reported. Decressac and colleagues also 
demonstrated that a significant portion of the overexpressed α-synuclein 
was phosphorylated at serine 129 (Decressac et al., 2012). Phosphorylated 
α-synuclein is abundantly expressed in Lewy bodies (Anderson et al., 2006). 
Importantly, it is thought to potentiate the toxicity of α-synuclein 
(Gorbatyuk et al., 2008; Sato et al., 2011) and can modulate the formation 
of Lewy bodies (reviewed by Tenreiro et al., 2014). It may be that the 
differences seen between that study and the present study may be 
explained by alterations in the proportion of α-synuclein that is 
phosphorylated within the nigrostriatal system. Moreover, the recent 
discovery of cross-hemispheric dopamine projections that can modulate 
contralateral dopamine transmission (Fox et al., 2016) may contribute to the 
moderate reduction seen in striatal TH-positive fibres that we observed. 
Nevertheless, we have demonstrated that bilateral administration of AAV-
α-synuclein reproduces the primary pathological features of PD and is a 
viable alternative to unilateral animal models of PD.  
 Due to the complexity of analysing gross motor function, a series of motor 
tests was carried out to accurately assess and identify any motor impairment 
across a wide range of parameters. Using this paradigm, we found that 
unilateral AAV-mediated overexpression of α-synuclein induced significant 
impairment in the stepping test only, but not in the cylinder test or the 
corridor test. Previous work investigating behavioural effects of distinct 
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degrees of lesions of the nigrostriatal system induced by striatal 
administration of 6-OHDA also found that animals that received partial 
lesions, induced by a lower dose of 6-OHDA at a single site as opposed to 
multiple injections, showed minor effects in the stepping test before other 
motor tests (Kirik et al., 1998). This substantiates our study which only 
demonstrated deficits in this task. Furthermore, our data is in line with 
previously a published study that used an AAV2/5 viral vector, which 
demonstrated that, despite significant nigral dopaminergic neuronal loss 
and decreased TH-immunoreactivity in the striatum, unilateral intra-nigral 
administration of AAV-α-synuclein was not sufficient to induce lateralised 
motor impairment (Naughton et al., 2017). Animals displayed significant 
motor deficits in the stepping test as well as the cylinder and whisker tests 
only when administration of AAV2/5- α-synuclein was combined with 
administration of the organic pesticide rotenone, leading the authors to 
conclude that the dose of AAV-α-synuclein used was “subclinical” (Naughton 
et al., 2017). Specifically, in that study animals were administered with 2 x 
1010 viral genomes (vg) of AAV2/5, and in this study animals were 
administered with 3.1 x 108 gc of AAV2/6, however due to the different 
titration methods used across these studies it is difficult to directly compare 
the doses.  
Given that lateralised motor tasks are only appropriate in animals that have 
received unilateral lesions, in this study animals that were administered with 
bilateral AAV-GFP or AAV-α-synuclein were assessed for motor dysfunction 
using the rotarod. Overexpression of α-synuclein had no effect on the 
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latency to fall off the rotarod apparatus. Moreover, the performance of all 
groups changed over time. Given that this is an upward trend in duration of 
time spent on the rotarod, it is likely that the animals became habituated to 
both the apparatus and the protocol over time, perhaps reflecting intact 
motor learning in all groups of animals. These animals received the same 
total dose of viral vector as the groups administered unilaterally, but it was 
divided equally across both hemispheres so it is likely that overall motor 
dysfunction could take longer to manifest in comparison. In future studies, 
a rotarod protocol incorporating more training sessions may allow for more 
subtle effects of α-synuclein overexpression to be elucidated.  
Despite the detection of α-synuclein-positive immunostaining in the dentate 
gyrus of the hippocampus, the behavioural results from hippocampal-
associated tasks were variable. Overexpression of α-synuclein had no effect 
on the percentage of alternations in a spontaneous alternations task. 
Moreover, the reduction in the number of entries and enhanced 
performance by all groups over the course of the experiment suggest that 
repeated exposure to the apparatus and test paradigm resulted in 
habituation by the animals. This task is reflective of working memory, in that 
every response varies in accordance to the arm chosen each time (Sherrick 
et al., 1979) , and it exploits the animal’s natural tendency to explore its 
environment. However, it is not without its caveats. Deacon and Rawlins 
(2006) described two main disadvantages to the spontaneous alternations 
protocol. Firstly, they state that the continuous nature of the task 
contributes to inter-trial interference and results in moderate alternation 
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rates typically seen in this paradigm. Secondly, animals with hippocampal 
damage notoriously adopt side preferences and thus could perform 
adequately in this task given it’s continuous nature (Deacon and Rawlins, 
2006). To combat these issues, they suggest that a discrete trial procedure 
is more suitable for detecting hippocampal damage; this protocol could be 
adopted in future studies.  
The social recognition paradigm employed in this study measures short-term 
social memory, specifically the ability of an animal to recognise and 
remember a juvenile rat encountered 30 min previously. Recent evidence 
points to the involvement of a number of brain regions and 
neurotransmitter systems in the consolidation and retrieval of social 
recognition memory, including the dopaminergic systems in the 
hippocampus and basolateral amygdala (Garrido Zinn et al., 2016; Tanimizu 
et al., 2017). Moreover, social recognition memory has been shown to be at 
least partially dependent on adult hippocampal neurogenesis (Pereira-
Caixeta et al., 2016). In this study, animals that received AAV-α-synuclein 
bilaterally spent significantly more time investigating the juvenile rat on the 
second presentation, indicating that they did not recognise the rat from the 
first presentation. This is similar to previous work demonstrating that 
bilateral administration of 6-OHDA could induce deficits in social recognition 
memory (Tadaiesky et al., 2008). In the present study, animals that received 
unilateral AAV-α-synuclein did not show significant deficits in social 
recognition, however the discrimination ratio for this group was higher than 
controls. In this testing paradigm, it is postulated that animals with intact 
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social memory capabilities would spend less time exploring the juvenile rat 
during the second presentation, thus the calculated discrimination ratio 
would be less than 0.5 (“chance level”, i.e. equal time spent exploring in each 
presentation). Given that the discrimination ratio for the AAV-α-synuclein 
unilateral group is higher than this, albeit marginally, it is possible that this 
group did display some form of social recognition impairment, however the 
intact contralateral hemisphere compensated for this functional 
impairment. Interestingly, animals that received unilateral AAV-GFP also 
showed deficits in social recognition. 
Olfactory deficits are a common NMS in patients with PD (Hawkes et al., 
1997), and they can often be present years preceding diagnosis (Postuma et 
al., 2012). Olfactory dysfunction has been demonstrated in animal models 
of PD such as the 6-OHDA model (Kumari et al., 2015; Tadaiesky et al., 2008) 
and the MPTP model (Castro et al., 2012), however to date there has been 
no investigation of olfactory deficits in the AAV-α-synuclein model. In this 
study, we used a previously published paradigm that involves a rat 
distinguishing between a novel odour (fresh cage bedding) and a familiar 
odour (its own used bedding). Although previous work has stated that this 
protocol relies on an animal showing preference for its own scent as 
opposed to a novel scent (Tadaiesky et al., 2008), we suggest that actually, 
the opposite is true. We have previously mentioned that an animal’s natural 
tendency is to explore a novel environment, a feature that is exploited in 
many behavioural tasks such as spontaneous alternations in the Y-maze. In 
light of this, it seems likely that the same is true for this olfactory 
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discrimination task; an animal can recognise a novel odour over its own 
familiar odour and thus spend more time in the novel compartment. In this 
study, we show that control animals spent significantly more time in the 
novel compartment when compared to all other groups. Moreover, all 
groups increased the time spent in the novel compartment as the 
experiment progressed, and this was coupled with decreased number of 
entries, indicative of habituation to the test protocol. Our data is supported 
by a recent study employing the rotenone model in adult male rats, which 
also demonstrated control animals spent significantly more time in the novel 
compartment compared to familiar (Rodrigues et al., 2014). Although 
olfactory function is primarily associated with the olfactory bulb, the 
connections between the olfactory bulb and the hippocampus have been 
shown to be critical in odour sampling and processing (Chapuis et al., 2013; 
Gourevitch et al., 2010). Moreover, growing data supports a role for 
dopamine in olfactory processes, as  blocking dopamine receptors in the 
olfactory bulb has been shown to negatively affect odour discrimination 
(Escanilla et al., 2009), and more recently a new dopaminergic nigro-
olfactory projection has been identified (Höglinger et al., 2015). In this study, 
it is likely that the combination of α-synuclein pathology in the SN and 
hippocampus and associated reductions in dopaminergic neurons could be 
sufficient to induce deficits in olfactory function.   
Taken together, it is clear that overexpression of α-synuclein in the SN can 
lead to propagation of the protein to the hippocampus, and that there it can 
significantly affect a number of hippocampal-associated behavioural tasks. 
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However, these effects are variable and so future studies may require more 
sensitive and specific tests to fully elucidate the subtle effects of α-synuclein 
expression in the hippocampus. Nevertheless, our data is in line with other 
published studies that have repeatedly demonstrated the ability of α-
synuclein to propagate through interconnected brain regions (Luk et al., 
2012; Mason et al., 2016; Paumier et al., 2015; Rey et al., 2013). 
Furthermore, it is the capacity of α-synuclein to proliferate throughout the 
brain that has led to PD being considered as a prion-like disorder (reviewed 
by Brundin et al. 2016), and so any viable animal model of the disease must 
be able to replicate this.  
Conditioned taste aversion is a classic conditioning paradigm and is 
associated with the basolateral amygdala (Osorio-Gómez et al., 2016), as 
well as the prefrontal cortex (Gonzalez et al., 2015) and insular cortex 
(Martinez-Moreno et al., 2016). A conditioned taste aversion is established 
when the taste of food (conditioned stimulus, CS) is followed by sickness 
(unconditioned stimulus, US). Generally, animals are quickly able to learn 
the association between the CS and the US, and the hedonic aspect shifts 
from positive to negative (reviewed by Yamamoto and Ueji, 2011). In this 
study, we employed sucrose as the CS and the malaise and nausea induced 
by lithium administration as the US. Thus, comparing the percentage of 
sucrose consumption in animals that received a saline (control) injection to 
animals that received a lithium injection is a measure of the success of the 
conditioned aversion. Overexpression of α-synuclein had no effect on the 
ability of animals to display aversive behaviour, as both AAV-α-synuclein 
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unilateral and bilateral animals consumed significantly less sucrose solution 
when compared to the corresponding controls. Indeed, α-synuclein-positive 
immunostaining was not detected in the amygdala, which substantiates the 
behavioural data. However, animals that received AAV-GFP bilaterally did 
not display a significant difference in percentage sucrose consumption when 
compared to their control counterparts, indicating that they did not develop 
the taste aversion. Although animals in this group showed a clear preference 
for sucrose during acquisition, and at levels similar to control animals, during 
the test phase they consumed significantly less sucrose when compared to 
controls. This may serve to confound the differences in preference 
percentage and perhaps explain this result.  
To conclude, in this study we have shown that unilateral and bilateral 
administration of AAV-α-synuclein induced distinct patterns of nigrostriatal 
degeneration in adult male SD rats. Specifically, animals injected with 
bilateral AAV-α-synuclein demonstrated a more robust combination of 
nigral dopaminergic neuronal degeneration as well as associated loss of TH-
positive fibres in the striatum. Moreover, unilateral overexpression of AAV-
α-synuclein induced deficits in the olfactory discrimination task while 
bilateral overexpression of AAV-α-synuclein induced deficits in both the 
olfactory discrimination and the social recognition tasks. We show that the 
AAV-α-synuclein rat model can reproduce the proliferation of α-synuclein 
throughout the brain, and that it appears that is at least partially dependent 
on the duration of expression. Moreover, this model can be used to replicate 
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NMS associated with the disease, although more sensitive behavioural tasks 














6.0 Neuroprotective effects of voluntary running 
on non-motor symptoms in an α-synuclein rat 







Parkinson’s disease (PD) is no longer primarily classified as a motor disorder 
due to the emergence of a number of non-motor symptoms of the disease, 
including cognitive dysfunction. These non-motor symptoms are highly 
prevalent and greatly affect the quality of life of patients with PD, and so 
therapeutic interventions to alleviate these symptoms are urgently needed. 
The aim of this study was to investigate the potential neuroprotective effects 
of voluntary running on cognitive dysfunction in an AAV-α-synuclein rat 
model.  Bilateral intranigral administration of AAV-α-synuclein was found to 
induce motor dysfunction and a significant loss of nigral dopaminergic 
neurons, neither of which were rescued by voluntary running. 
Overexpression of α-synuclein also resulted in significant impairment on a 
neurogenesis-dependent pattern separation task, as well as anxiety-like 
behaviours on both the open field and the elevated plus maze. Voluntary 
running improved performance on the pattern separation task only. This was 
substantiated by an effect on hippocampal neurogenesis levels in the dorsal, 
and not ventral, dentate gyrus, suggesting that the functional effects on 










Recently, due to the increasing awareness of NMS in PD, the disease has 
begun to be recognised as a multifactorial syndrome rather than simply a 
motor disorder (reviewed by Titova et al. 2016). In order to increase the 
translational impact of preclinical research, there is an urgent need for 
animal models that can reproduce these NMS and so represent a more 
accurate depiction of the human disease. In chapter 5, we showed that 
bilateral intranigral administration of AAV-α-synuclein was a robust model 
of PD, resulting in dopaminergic neuronal degeneration in the SN as well as 
bilateral propagation of α-synuclein through the brain. More specifically, we 
demonstrated α-synuclein expression throughout the hippocampus, 
including in the dentate gyrus. Interestingly, the dentate gyrus is one of only 
two distinct niches in the brain whereby neurogenesis has been proven to 
occur throughout the adult lifespan (Altman, 1969; Eriksson et al., 1998). 
These newly born neurons have been shown to contribute to learning and 
memory processing, particularly pattern separation (Clelland et al., 2009), as 
well as emotional regulation (reviewed by Oomen et al. 2014). Inhibition or 
ablation of neurogenesis in animal models has been shown to increase 
anxiety and depressive-like behaviour and impair performance in cognitive 
tasks (reviewed by Ryan & Nolan 2016); conversely enhancing neurogenesis 
using methods such as environmental enrichment (reviewed by 
Bekinschtein et al., 2011), dietary restriction (reviewed by Morgan et al., 
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2017) or aerobic exercise can alleviate these mood disturbances and 
improve cognitive performance (Creer et al., 2010; Hill et al., 2015).  
The first link between exercise and PD was published by Sasco and 
colleagues (1992), who demonstrated that moderate exercise during 
adulthood can protect against the risk of developing a PD in later life (Sasco 
et al., 1992). This has been further strengthened by the recent publication 
of a large-scale prospective epidemiological study that also confirms the 
association (Yang et al., 2015). Moreover, exercise has also been shown to 
play a role in restoring motor function (Collett et al., 2017; Santos et al., 
2017) and alleviating NMS in patients already diagnosed with PD (reviewed 
by Cusso et al. 2016 and Dashtipour et al. 2015).  
Given the previous chapters finding that α-synuclein propagates from the SN 
to the dentate gyrus, the role this region plays in specific cognitive and 
emotional functioning and it’s potential to be modulated with interventions 
such as exercise, the aims of this chapter are: 
a) To investigate the effects of AAV-α-synuclein overexpression on specific 
hippocampal-associated behaviours, including pattern separation 
b) To examine the potential neuroprotective effects of aerobic exercise on α-
synuclein-induced cognitive dysfunction 
c) To elucidate the mechanisms of exercise-induced neuroprotection, 




6.3 Experimental design 
6.3.1 Animal husbandry 
Adult male Sprague Dawley rats (Envigo, UK) were maintained on a 12h:12h 
light: dark cycle (lights on at 08.00h) under regulated temperature (21±2°C) 
and humidity (30-50%) and pair-housed. Standard rat chow and water were 
available ad libitum, unless behavioural testing dictated otherwise 
temporarily. All experiments were conducted in accordance with the 
European Directive 2010/63/EU, and under an authorisation issued by the 
Health Products Regulatory Authority Ireland (HPRA, AE19130/P010) and 
approved by the Animal Ethics Committee of University College Cork 
(approval number 2013/030). 
Stereotaxic surgery 
All surgery was conducted under general anaesthesia induced by inhaled 
isoflurane. Due to concerns regarding toxicity of long-term expression of 
AAV-GFP from the previous chapter, in this study sham animals were 
administered with sterile 0.9% NaCl. Briefly, animals were placed in a 
stereotaxic frame (Kopf Instruments) and an incision was made through to 
the skull. Animals were administered with 3 µl of either AAV-α-synuclein (3.1 
x 109gc/3µl) or 0.9% sterile saline solution (sham) bilaterally into the SN at 
co-ordinates AP -5.3, ML ±2.0 and DV -7.2 relative to bregma. All solutions 
were infused at a rate of 1 µl/min, with an additional 2 min allowed for 
diffusion before the needle was withdrawn. Following injection, the incisions 
were sutured and rats were allowed to recover on a heating mat before 
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returning to their home cages. Animals were administered the analgesic 
carprofen (Rimadyl® 5mg/kg, s.c., Zoetis Ireland Ltd) and 5% glucose solution 
immediately following the procedure.  
 
6.3.2 Experimental design 
One week following surgery, animals were administered with i.p. BrdU 
(Sigma, Ireland) 75mg/kg in 4 doses, each 2h apart. They were randomly 
divided into 4 groups; ‘sham + sedentary’ (n = 7), ‘α-synuclein + sedentary’ 
(n = 8), ‘sham + running’ (n = 6) and ‘α-synuclein + running’ (n = 8), and were 
pair-housed in either cages with free access to running wheels (‘running’ 
groups) (Activity wheel, Techniplast, UK) or standard housing cages 
(‘sedentary’ groups). Running wheels were connected to counters which 
allowed wheel revolutions to be continuously monitored. Motor and 
cognitive testing was carried out at selected time-points following surgery 
based on the previous study (see Figure 6.1 for experimental timeline).  
 
 
Figure 6.1 Experimental design 
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6.3.3 Behavioural testing 
Behavioural testing was carried out as described previously (Section 4.6.2), 
and carried out at the time-points detailed in figure 6.1. 
 
6.4 Results 
6.4.1 Running distance and body weights 
 
There was no significant difference in the average distance run per month 
between animals that were administered AAV-α-synuclein or those 
administered saline (F [1,5] = 0.03, p = 0.86; Figure 6.2A). Both groups of 
animals ran significantly more in the initial 10 weeks of the experiment 
compared to baseline (F [9,45] = 15.5, p < 0.0001), however this declined at 
later time-points. Animals in all groups gained weight over the course of the 
experiment (F[9,207] = 862, p < 0.001; Figure 6.2B), however animals in the 
running groups weighed significantly less than their sedentary counterparts 
(F[1,23] = 20.97, p = 0.00013). Overexpression of α-synuclein had no effect 
on weight gain (F[1,23] = 0.14, p = 0.71).  
 
6.4.2 Overexpression of α-synuclein into SN and associated motor 
impairment 
 
Both groups of animals that received AAV-α-synuclein displayed extensive 
transduction of dopaminergic neurons in the SN. There was no difference in 
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the number of co-localised TH+/α-syn+ neurons between the groups (t (4) = 
0.89, p = 0.42; Figure 6.3A). AAV-mediated overexpression of α-synuclein 
resulted in a significant degeneration in the number of dopaminergic 
neurons in the SN and this was persistent across each level of the SN (AP -
5.2, F [1,3] = 813, p < 0.0001; AP -5.6, F[1,4] = 19.45, p = 0.01; AP -6.0, F[1,4] 
= 8.6, p = 0.04; Figure 6.3B). 
Voluntary running increased the number of dopaminergic neurons, only at 
the level immediately proximal to the administration site (AP -6.0, F [1,3] = 
52.92, p = 0.005). There was a trend towards a significant reduction in TH-
positive immunostaining in the striatum in the AAV-α-synuclein groups 
compared to sham controls (F [1,135] = 3.15, p = 0.07; Figure 6.3C), and a 
priori post hoc analysis revealed this was specific to the sedentary groups 
(sham sedentary vs α-synuclein sedentary p = 0.06). The degeneration of 
dopaminergic neurons in the SN caused by α-synuclein overexpression led 
to a significant impairment in sensorimotor integration on the rotarod (F 
[1,37] = 5.26 p = 0.02; Figure 6.3D). Voluntary running had no effect on 
motor function in the same task (F [1,37] = 0.33, p = 0.56). 
 
6.4.3 General locomotor activity 
Voluntary running had no impact on the distance travelled (F [1, 23] = 0.57, 
p=0.45) or the average velocity (F [1, 23] = 0.57, p = 0.45) of the animals in 
the open field test. Overexpression of α-synuclein resulted in a hyperactive 
phenotype, with animals travelling a significantly greater distance than 
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controls (F [1, 23] = 4.4, p=0.045; Figure 6.4A) and at a significantly higher 




Figure 6.2. (A) Average running distance per month of sham and AAV-α-synuclein groups. (B) 
Average weight gain over the course of the experiment. Data are shown as mean ± SEM and 






Figure 6.3 (A) The percentage transduction efficiency of the AAV viral vector in both sedentary and 
running α-synuclein groups. (B) TH-positive cell counts in the SN and (C) fluorescence intensity of TH-
positive immunostaining in the striatum. (D) Motor performance measured on the rotarod. 
Representative images of (E, H) TH-positive cells in the SN, (F, I) α-synuclein expression in the SN and 
(G-J) merged images. Scale bar represents 100 µm. Data are expressed as mean ± SEM, *p<0.05, 





Figure 6.4 General locomotor activity measured by (A) distance travelled and (B) velocity travelled in 
the open field. Data are shown as mean ± SEM and analysed using 2-way factorial ANOVA and post 










6.4.4 Hippocampal-associated memory tasks 
 
The percentage of alternations in a standard discrete alternation task was 
not affected by overexpression of α-synuclein (F [1,22] = 0.86, p=0.36; Figure 
6.5A) or by voluntary running (F [1,22] = 1, p= 0.32). A priori testing revealed 
a trend towards a significant impairment in this task in α-synuclein 
compared to sedentary groups (t (11) = 1.92, p = 0.08). To increase the 
cognitive load of the task, a 1 min delay was inserted into the protocol. 
However, neither overexpression of α-synuclein (F [1,22] = 0.46, p = 0.5; 
Figure 6.5B) or voluntary running (F [1,22] = 0.73, p = 0.4) had an effect on 
the percentage of alternations in this paradigm.  
In the modified spontaneous location recognition task, there was no effect 
of α-synuclein (F [1, 20] = 0.001, p =0.99) or voluntary running (F [1, 20] = 
0.56, p = 0.46) on the ability of the animals to discriminate between the 
novel and familiar object locations in the large separation paradigm (Figure 
6.5C). However, in the small separation paradigm, voluntary running 
significantly enhanced the discrimination ratio compared to that of the 
sedentary counterparts (F [1, 22] = 11.64, p=0.002; Figure 6.5D). There was 




Figure 6.5 The percentage of alternations in (A) a standard discrete alternations protocol and (B) with 
a 1 min delay. Modified spontaneous location recognition test in both (C) a large separation paradigm 
and (D) a small separation paradigm. Data are shown as mean ± SEM and analysed using 2-way 
factorial ANOVA and post hoc Fisher’s LSD, **p<0.01 running vs sedentary counterparts, #p<0.05 vs 
α-synuclein sedentary.  
 
impairment in performance of the same task by α-synuclein groups 
compared to sham groups (F [1, 22] = 3.24, p=0.08), and a priori post hoc 
analysis revealed that voluntary running rescued the partial deficit that was 
evident in α-synuclein groups (α-synuclein sedentary vs α-synuclein running 





These data indicating a deficit in hippocampal-associated tasks are 
substantiated by the observation of human α-synuclein expression in the 
dentate gyrus (Figure 6.6), showing that α-synuclein was transported to this 
brain area following administration of AAV-α-synuclein into the SN.  
 
 
Figure 6.6 Representative photomicrographs of α-synuclein staining in the dentate gyrus of (A, B) AAV-
α-synuclein + sedentary and (C, D) AAV-α-synuclein + running groups. Images taken at (A, C) 10x and 







6.4.5 Anxiety-related behaviours 
 
Testing in the elevated plus maze revealed that overexpression of α-
synuclein resulted in the animals spending significantly more time in the 
closed arms of the maze when compared to control animals (F [1, 23] = 
18.95, p=0.0002; Figure 6.7A) Voluntary running also increased the amount 
of time spent in the closed arms in comparison to sedentary animals (F [1, 
23] = 4.39, p=0.04). Factorial ANOVA showed a significant interaction effect 
(treatment x running, F [1, 23] = 9, p=0.006), and post hoc analysis revealed 
a significant difference between the control sedentary and the α-synuclein 
running groups (p=0.02), and a small effect of α-synuclein on the non-
running animals (saline sedentary vs α-synuclein sedentary, p=0.08). Neither 
overexpression of α-synuclein (F [1, 23] = 0.14, p=0.7; Figure 6.7B) or 
voluntary running (F [1, 22] = 0.89, p=0.35) had any impact on the total 
number of closed arm entries per group.  
In the open field, overexpression of α-synuclein resulted in a significant 
increase in thigmotaxis behaviour, as measured by the time the animals 
spent in the border zone of the open field arena, compared to sham controls 
(F [1, 23] = 5.5, p =0.027; Figure 6.7C), Voluntary running did not affect 




Figure 6.7 (A) Percentage of time spent in the closed arms of the elevated plus maze and (B) total 
number of entries into the closed arms. (C) Thigmotaxis behaviour measured by time spent in the 
border zones of the open field. Data are shown as mean ± SEM and analysed using 2-way factorial 
ANOVA and post hoc Fisher’s LSD, *p<0.05, ***p<0.001 vs corresponding sham controls, #p<0.05 vs 










6.4.6 Olfactory discrimination 
 
Overexpression of α-synuclein did not affect the percentage of time spent 
by the animals in the novel compartment (F [1, 23] = 1.45, p=0.24; Figure 
6.8), nor was there a difference in the animal’s performance between time 
points (F [1, 23] = 0.97, p=0.33).  Voluntary running significantly decreased 
the amount of time spent by the animal in the novel compartment (F [1, 23] 
= 5.8, p=0.02). Post hoc analysis revealed that this effect was specific to α-




Figure 6.8 Performance in an olfactory discrimination task. Data are shown as mean ± SEM and 
analysed using 2-way repeated measures ANOVA and post hoc Fisher’s LSD *p<0.05 vs corresponding 







6.4.7 Hippocampal neurogenesis 
 
The total number of DCX-positive cells in the dentate gyrus was significantly 
decreased by overexpression of α-synuclein (F [1,12] = 5.12, p = 0.043; Figure 
6.9E). Subdivision of dentate gyrus regions revealed that this effect was 
specific to the dorsal (F [1,12] = 8.07, p = 0.01) and not found in the ventral 
region (F [1,12] = 0.16, p = 0.69). Voluntary running had no effect on the 
number of DCX-positive cells in the dentate gyrus (F [1,23] = 0.54, p = 0.47).  
Overexpression of α-synuclein in the SN significantly decreased the total 
number of BrdU-positive neurons in the dorsal dentate gyrus (F[1,12] = 
18.31, p = 0.001; Figure 6.10E) and this effect was persistent in the sub-
regions of the dentate gyrus, including the granule cell layer  
(F[1,12] = 4.94, p = 0.04) and the subgranular zone (F[1,12] = 12.38, p = 
0.004; Figure 6.10E). Factorial ANOVA showed a significant interaction effect 
(treatment x running F[1,12] = 7.1, p = 0.02). Post hoc analysis revealed that, 
although voluntary running alleviated α-synuclein-induced deficits in the 
number of BrdU-positive cells (α-synuclein sedentary vs α-synuclein running, 
p = 0.006), this effect was specific to the dorsal subgranular zone (α-
synuclein sedentary vs α-synuclein running, p = 0.003). Neither 
overexpression of α-synuclein (F[1,12] = 2.97, p = 0.1) nor voluntary running 
(F[1,12] = 1.36, p = 0.26) affected the number of BrdU-positive cells in the 






Figure 6.9 DCX-positive immunostaining in the dentate gyrus of the hippocampus in (A) Sham + 
sedentary (B) AAV- α-synuclein + sedentary (C) Sham + running and (D) AAV-α-synuclein + running 
groups. (E) Number of DCX+ cells in the total, dorsal and ventral dentate gyrus. Data are shown as 
mean ± SEM and analysed using 2-way factorial ANOVA and post hoc Fisher’s LSD, *p<0.05 vs 








Figure 6.10 BrdU+ neurons (indicated by the arrows) in the dentate gyrus in (A) sham + sedentary, (B) 
AAV-α-synuclein + sedentary, (C) sham + running and (D) AAV-α-synuclein + running groups. BrdU+ 
neurons in the granule cell layer (GCL) and subgranular zone (SGZ) in the (E) dorsal (F) and ventral 
dentate gyrus. Data are shown as mean ± SEM and analysed using 2-way factorial ANOVA and post 
hoc Fisher’s LSD, *p<0.05, ***p<0.001 vs corresponding saline control, #p<0.05 vs α-synuclein 





A growing body of evidence supports the Braak hypothesis (Heiko Braak et 
al., 2003), which states that the aggregation and propagation of α-synuclein 
throughout the brain is responsible for the array and progression of motor 
and NMS experienced by PD patients. Moreover, it has been proven that the 
neuropathological staging of the disease correlates with cognitive decline 
(Braak et al., 2006b). In this study, we show that bilateral overexpression of 
α-synuclein in the SN not only causes degeneration of nigral dopaminergic 
neurons and motor impairment, but that it also leads to deficits in 
hippocampal-associated memory tasks, specifically in tasks assessing the 
ability to “pattern separate”. Furthermore, we show that these deficits are 
linked to alterations in adult hippocampal neurogenesis in the dentate gyrus.  
AAV-mediated overexpression of α-synuclein has been well-characterised in 
the literature as a viable animal model of PD (reviewed by Lindgren et al. 
2012). It is the only model to date that replicates all of the 
neuropathological, neurochemical and behavioural features of the disease, 
including the formation of α-synuclein aggregates in nigral neurons (Kirik et 
al., 2003). The majority of the work published to date employs the model 
unilaterally, using lateralised tasks such as the cylinder test and the stepping 
test to measure motor dysfunction and allowing the contralateral 
hemisphere to act as a control in post mortem analyses. Here, we show that 
bilateral administration of α-synuclein induces bilateral nigral dopaminergic 
167 
 
degeneration and a decrease in striatal TH innervation, which subsequently 
causes bilateral motor dysfunction that can be measured on a rotarod. 
Although the degree of striatal denervation was not as profound as that seen 
in animal with acute lesions of the nigrostriatal system such as those induced 
by stereotaxic injections of 6-OHDA, it was sufficient to result in a significant 
degree of motor impairment. Previous work by Kirik and colleagues (1998) 
described the different thresholds of TH-positive fibre loss in the rat striatum 
that are necessary to induce motor impairment on specific laboratory tasks. 
They showed that a 40-50% reduction in TH innervation was required to 
induce detectable deficits in the apomorphine-induced rotations task, but 
that 70-80% reduction was necessary for significant motor impairment in the 
stepping test and in a modified paw-reaching test (Kirik et al., 1998). It is 
worth noting that this work was carried out using the unilateral 6-OHDA 
model, and so although the results cannot be directly compared to the 
present study, the underlying premise that different degrees of striatal 
denervation are required to detect motor deficits on different tasks remains 
valid. 
In the present study, voluntary running did not alleviate motor dysfunction, 
nor did it rescue the partial degeneration of dopaminergic nerve terminals 
in the striatum. Interestingly, voluntary running did protect against TH-
positive neuronal loss in the SN immediately proximal to the administration 
site of the viral vector. However, this neuroprotective effect was not 
sufficient to improve motor function. To our knowledge, this is the first study 
to investigate the effects of voluntary running on motor and NMS in an α-
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synuclein model of PD. Although several reports have employed exercise as 
an intervention in other animal models of PD including the MPTP model 
(Jang et al., 2017), the rotenone model (Shin et al., 2017) and the 6-OHDA 
model (Landers et al., 2013; Tillerson et al., 2003), results are highly variable 
and again, these models are not the most representative of the human 
disease when compared to the AAV-α-synuclein model (reviewed by 
Volpicelli-Daley et al., 2016).  
The rotarod protocol used in this study was a fixed speed test. A previous 
study, albeit one using the 6-OHDA model, has shown that an accelerating 
rotation rate on the rotarod allows a more specific correlation between 
motor deficits and lesion size (Monville et al., 2006). This is supported by the 
recent publication of a study by Wang and colleagues, who demonstrated 
that despite modest loss of TH-positive fibres in the striatum after intra-
striatal administration of 6-OHDA (approximately 20% less than control 
animals), an accelerating rotarod protocol was sufficiently sensitive to 
detect motor dysfunction (Wang et al., 2013). Nonetheless, our results are 
in line with previously published work where bilateral administration of α-
synuclein induced TH-positive cell loss in the SN and corresponding TH-
positive fibre loss in the adult rat striatum, coupled with mild motor deficits 
on a ledged beam-walking test (Caudal et al., 2015). Furthermore, this also 
highlights the variability in tests used to measure motor impairment in 
bilateral models of PD. There are a number of different rotarod protocols 
currently published, which use distinct training paradigms and different 
testing speeds (Goes et al., 2014; Marei et al., 2015; Wang et al., 2013); this 
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makes it difficult to extrapolate between the results of these studies.  Gait 
disturbances and postural instability are classic motor symptoms of PD 
(reviewed by Sveinbjornsdottir 2016) and recent evidence suggests that gait 
analysis may be a more sensitive and specific method of detecting motor 
dysfunction in animal models of movement disorders (Vandeputte et al., 
2010). Studies carried out on rats with bilateral 6-OHDA lesions confirms 
that these animals display a wide variety of gait disturbances post-lesion, 
including alterations in stride length, swing speed and stance duration; 
furthermore these symptoms are sensitive to L-dopa therapy (Westin et al., 
2012). Moreover, gait disturbances can be used to differentiate between 
lesions induced by 6-OHDA administration into the striatum, into the MFB 
and into the SN, and some aspects of gait impairments positively correlate 
with the extent of loss of TH-positive cells in the SN (Zhou et al., 2015). 
Similarly, a time-course of gait analysis after a unilateral 6-OHDA lesion has 
been shown to be more sensitive to motor deficits and compensatory 
mechanisms than the apomorphine-induced rotations test (Hsieh et al., 
2011). To our knowledge, there is currently no data investigating gait 
disturbances in the AAV-α-synuclein rat model, however the technology is 
available and has been relatively well characterised and so this remains a 
possible avenue for future investigation. 
Overexpression of α-synuclein in this study resulted in a hyperactive 
phenotype, exemplified by animals travelling greater distances and at higher 
velocities than sham animals. This confirms previous work by Aldrin-Kirk and 
colleagues (2014), who showed that administration of an AAV6 viral vector 
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overexpressing α-synuclein into the forebrain of SD pups resulted in 
hyperactive behaviour in the open field after 40 weeks (9 months). This was 
coupled with a  significant degeneration of cholinergic interneurons in the 
striatum (Aldrin-Kirk et al., 2014). Although the exact role of cholinergic 
interneurons in the pathophysiology of PD is unclear, growing evidence 
suggests that these cells can modulate dopamine transmission in the 
striatum (Johnson et al., 2017; Kosillo et al., 2016), as well as modulating 
motor symptoms in animal models of PD (Kondabolu et al., 2016; Maurice 
et al., 2015; Ztaou et al., 2016). Interestingly, overexpression of α-synuclein 
in either a transgenic mouse line or through AAV administration in rats has 
been shown to reduce striatal dopamine levels, and it was suggested that 
this was via a direct effect on striatal cholinergic interneurons (Tozzi et al., 
2015).  
Cognitive impairment is a highly prevalent NMS in PD (Domellöf et al., 2015; 
Yarnall et al., 2014), and it can significantly impact upon the quality of life of 
PD patients (Bugalho et al., 2016; Kwon et al., 2016). Although there is a 
wealth of studies that have investigated cognitive impairment in animal 
models of PD, such as the 6-OHDA and MPTP models (reviewed by Lindgren 
& Dunnett 2012), relatively little has been published to date using the AAV-
α-synuclein rat model. One report by Campos and colleagues (2013) used 
bilateral nigral overexpression of α-synuclein in adult rats to investigate 
cognitive dysfunction, and showed that α-synuclein had no effect on 
performance in three versions of the MWM task, which measured working 
and spatial reference memory as well as cognitive flexibility (Campos et al., 
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2013). However, in that study, cognitive testing was carried out 7-8 weeks 
post-surgery and α-synuclein expression in the hippocampus was not 
confirmed, so it is possible that the testing point was too early to ensure that 
viral integration, α-synuclein expression and subsequent propagation to the 
hippocampus had occurred. In the present study, we show that although 
overexpression of α-synuclein had no effect on spatial working memory 
measured by a discrete alternations task, it significantly impaired the ability 
of animals to perform a pattern separation task. Pattern separation refers to 
the organisation of similar, overlapping episodic memories so that they may 
be recognised as singular and separate representations of each memory 
(Bekinschtein et al., 2013), and it has been shown to be uniquely dependent 
on adult hippocampal neurogenesis in the dentate gyrus (Clelland et al., 
2009). Moreover, increasing levels of adult hippocampal neurogenesis in 
rodents by environmental enrichment or voluntary running can also 
enhance performance in a pattern separation task (reviewed by 
Bekinschtein et al. 2011). In this study, we have demonstrated that long-
term voluntary running can rescue α-synuclein-induced deficits in a small 
pattern separation task, and that this is likely to be mediated by alterations 
in adult hippocampal neurogenesis. Overexpression of α-synuclein caused 
significant decreases in the number of immature neurons (DCX+ cells) and 
the survival of newly born neurons (BrdU+/NeuN+) in the dorsal, and not the 
ventral, dentate gyrus. Similarly, voluntary running increased the survival of 
neurons only in the dorsal dentate gyrus. This effect was localised to the 
subgranular zone, which has been shown to be the specific region of the 
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dentate gyrus associated with adult hippocampal neurogenesis (reviewed by 
Goncalves et al. 2016). The dentate gyrus is known to be involved in various 
cognitive and emotional processing, and it is functionally divided along its 
longitudinal axis whereby the dorsal dentate gyrus is associated with 
learning and memory and the ventral region regulates anxiety and stress 
resilience (reviewed by O’Leary & Cryan 2014).  
In this study, voluntary running did not ameliorate anxiety-like behaviour in 
the α-synuclein groups, measured by thigmotaxis behaviour in the open field 
or by behaviour in the elevated plus maze. Moreover, voluntary running 
increased the amount of time spent by animals in the closed arms of the 
elevated plus maze when compared to sedentary controls. Although running 
has been widely regarded to confer anxiolytic benefits in animals (Duman et 
al., 2008; Greenwood et al., 2003), these findings are becoming increasingly 
controversial. Recent work, albeit in mice, has shown that voluntary running 
can induce anxiety-like behaviour in a number of behavioural tasks including 
the open field task, the light/dark box and the FST (Fuss et al., 2010a). 
Moreover, deletion of running-induced hippocampal neurogenesis by 
focalized irradiation was sufficient to reverse the anxious phenotype (Fuss 
et al. 2010), suggesting that the enhanced levels of neurogenesis somehow 
played a role in generating the anxious behaviour. Although we found no 
evidence that overexpression of α-synuclein had impaired neurogenesis in 
the ventral dentate gyrus, α-synuclein overexpression did induce an anxiety-
like phenotype in both the open field and the elevated plus maze, suggesting 
alternative mechanisms in the regulation of these behaviours.  
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Olfactory discrimination is primarily functionally linked to the olfactory 
bulbs, however there is growing evidence to support a role for the olfacto-
hippocampal network in olfactory discrimination tasks (Gourevitch et al., 
2010; Knafo et al., 2005; Martin et al., 2007; Restivo et al., 2006; Uva and De 
Curtis, 2005). In this study, we show that overexpression of α-synuclein did 
not impact on an animal’s ability to discriminate between their own odour 
and a fresh bedding odour. However, voluntary running significantly 
affected the capacity for discrimination between novel and familiar odours. 
Although the olfactory bulb is an established site for adult neurogenesis in 
rats, the role of the newly-born neurons in olfactory processes and memory 
remains inconclusive (Bardy and Pallotto, 2010). Ablation of adult 
neurogenesis in the olfactory bulb has not consistently resulted in deficits in 
odour discrimination (reviewed by Kageyama et al. 2012 and  Lazarini & 
Lledo 2011), and so conversely enhancing neurogenesis such as in the 
present study may not lead to improved performance in an olfactory 
discrimination task. Perhaps a  more sensitive task, such as an odour delayed 
nonmatching to sample task that has previously been shown to be impaired 
in patients with hippocampal lesions (Levy et al., 2004) would be more 
appropriate in future studies.  
 To conclude, in this study we have shown that bilateral administration of 
AAV-α-synuclein into the adult rat SN results in bilateral degeneration of 
nigral dopaminergic neurons and of TH-positive fibres, as well as bilateral 
motor impairment measured on the rotarod. This model can also be used to 
replicate some of the primary NMS of PD, including hippocampal-associated 
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learning and memory tasks as well as anxiety-like behaviours. Moreover, we 
have shown that administration of AAV-α-synuclein into the adult rat SN can 
lead to the propagation and expression of α-synuclein in the dentate gyrus 
of the hippocampus where it can affect markers of adult hippocampal 
neurogenesis. Finally, we have shown that α-synuclein-induced deficits in a 
pattern separation task and associated alterations in hippocampal 




































Parkinson’s disease is the second most common neurodegenerative disease 
in the world (Ascherio and Schwarzschild, 2016), and given an ageing global 
population the incidence is expected to double by 2010 (Dorsey et al., 2007). 
Although there are a variety of therapies currently available to treat both 
motor and NMS of the disease, these are only used for symptomatic relief 
and do nothing to halt the disease process itself. Moreover, by the time 
patients begin to display motor symptoms, it is estimated that up to 30% of 
the dopaminergic neurons in the SN have already been lost (reviewed by 
Burke and O’Malley, 2013). Thus, research into effective preventative 
strategies is highly desirable.  
Given the difficulty in researching disease mechanisms in humans, a range 
of animal models of PD have been developed to allow comprehensive 
investigations of the neuropathological, neurobiological and neurochemical 
features of the disease. Each model has their own relative advantages and 
disadvantages (reviewed by Bové and Perier, 2012), however a recurring 
theme is the inability of any model to fully reproduce the progressive nature 
and Lewy body pathology that are characteristic of PD (reviewed by Lindgren 
et al., 2012 and Volpicelli-Daley et al., 2016), as well as the broad range of 
NMS that are also inherent to the disease (reviewed by Schapira et al., 2017). 
Moreover, the failure of many of the classic neurotoxin models to accurately 
predict translational success of neuroprotective compounds in clinical trials 
further hampers progress (reviewed by Athauda and Foltynie, 2015). The 
development of the AAV-α-synuclein model by Kirik and colleagues (2002) 
was in many ways a turning point, as it was able to replicate the behavioural 
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and neuropathological aspects of PD while also resulting in a progressive 
degeneration of dopaminergic neurons (Kirik et al., 2002). Since then, the 
model has enabled a wide range of critical preclinical research to be 
completed that would not have been possible in other neurotoxic models. 
The progressive nature of this model is one of its key features, as it has 
allowed for a more in-depth interrogation of the mechanisms of synaptic 
dysfunction when compared to other neurotoxin models such as 6-OHDA 
(reviewed by Volpicelli-Daley et al., 2016). Moreover, the AAV-α-synuclein 
overexpression model has also provided a more comprehensive overview of 
the role of α-synuclein in the pathogenesis of PD. For example, despite 
promising in vivo animal studies investigating the neuroprotective effects of 
NTFs such as GDNF, these results did not translate to successful clinical trials 
(reviewed by Olanow et al., 2015). By employing the AAV-α-synuclein model, 
Decressac and colleagues (2012c) established that overexpression of α-
synuclein in nigral dopaminergic neurons blocks GDNF signalling, providing 
a novel insight that would have been otherwise undiscovered in the 
neurotoxin models. Additionally, given that the AAV-α-synuclein model is 
most representative of the human disease, it has allowed for a more 
thorough investigation into putative therapeutic targets (reviewed by 
Volpicelli-Daley et al., 2016).  
The primary hypothesis of this thesis was that:  
The propagation of α-synuclein throughout the brain in PD is linked to the 
presence of NMS. 
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To test this hypothesis, this thesis employed the AAV-α-synuclein model 
overexpressing human wild-type α-synuclein to explore the ability of this 
model to replicate the proliferation of α-synuclein throughout the brain, and 
whether this could be linked to the pathogenesis of NMS. In study 1, we 
show that both unilateral and bilateral administration of AAV-α-synuclein 
induce distinct patterns of nigrostriatal degeneration. Interestingly, animals 
that received bilateral injections of AAV-α-synuclein demonstrated a more 
robust degeneration of dopaminergic neurons and TH-positive fibres in the 
striatum, confirming that this administration paradigm is a viable model of 
PD. We confirmed that both unilateral and bilateral overexpression of α-
synuclein in the SN induced bilateral propagation of α-synuclein throughout 
distinct regions of the brain, including the hippocampus, and that it can 
affect some aspects of hippocampal-associated behaviours. Given this data, 
we then focused on the impact of α-synuclein overexpression on specific 
cognitive and emotional tasks that are dependent on adult hippocampal 
neurogenesis. We also exmained the neuroprotective effects of exercise on 
α-synuclein-induced deficits in these tasks. In study 2, we show that bilateral 
administration of AAV-α-synuclein into the adult rat SN results in bilateral 
degeneration of nigral dopaminergic neurons and of TH-positive fibres, as 
well as bilateral motor impairment measured on the rotarod. Similarly, this 
model can be used to replicate some of the NMS associated with PD, 
including impairments in hippocampal-associated learning and memory 
tasks as well as anxiety-like behaviours. We demonstrated that 
administration of AAV-α-synuclein into the adult rat SN can lead to the 
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propagation and expression of α-synuclein in the dentate gyrus of the 
hippocampus where it can affect markers of adult hippocampal 
neurogenesis. Finally, we showed that α-synuclein-induced deficits in a 
pattern separation task and associated alterations in hippocampal 
neurogenesis can be alleviated by the neuroprotective effects of voluntary 
running. To summarise, we have proven our initial hypothesis; namely, this 
thesis confirms that the propagation of α-synuclein throughout the brain, a 
pathological feature inherent to PD, is linked to the pathogenesis NMS. More 
specifically, we have shown that overexpression of α-synuclein in the 
hippocampus results in significant impairment in hippocampal-associated 
tasks, some of which are dependent on neurogenesis.   
However, there are a number of limitations to the work presented in this 
thesis. One of the most difficult aspects of the present studies was finding 
suitable behavioural tasks that were sufficiently sensitive to detect the 
subtle effects of α-synuclein overexpression. Moreover, we also had to take 
into account significant expected motor impairment, and so initially we 
selected tasks that did not overly rely on the locomotor ability of each 
animal. In study 1, although we detected α-synuclein in the hippocampus in 
animals that were administered with both unilateral and bilateral AAV-α-
synuclein, there were no clear behavioural effects as a result of this. 
Similarly, the extent of motor impairment that we observed was not directly 
comparable to previously published studies. In light of this, for study 2 we 
increased the dose of viral vector administered, and focused on behavioural 
tasks that assessed specific cognitive domains, such as pattern separation.  
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More generally, there are difficulties in extrapolating the data from this 
thesis to both the human condition and the wider community. Under 
experimental conditions, it is possible to link specifics of the AAV-α-synuclein 
model, for example post mortem analysis of the extent of dopaminergic 
neuronal degeneration, to motor dysfunction. Similarly, in the exercise 
paradigm, an output such as distance run daily/weekly/monthly or levels of 
neurogenic markers can be correlated to performance in cognitive tasks. 
However, to compare results gleaned from an experimental model in an 
outbred rat strain to the heterogenous nature of PD in the human 
population is obviously quite a leap. Nevertheless, any information that can 
be gained from preclinical research in some way contributes to the greater 
knowledge in the field, and the more representative the animal model is, the 
higher the translational impact of the work.     
Furthermore, despite the many advantages of the AAV-α-synuclein model 
when compared to other neurotoxic animal models of PD, it is not without 
its caveats. Firstly, despite both genetic and pathological evidence that α-
synuclein is inherently linked with the disease process (Polymeropoulos et 
al., 1997; Spillantini et al., 1997), there is still no known endogenous function 
for the protein. Its localisation at presynaptic nerve terminals and its 
interaction with membrane proteins suggest that it plays a role in 
neurotransmitter release (Bendor et al., 2013). Additionally, it has been 
shown to be involved in vesicular trafficking (reviewed by Lautenschlager et 
al., 2017) and dopamine transmission (Butler et al., 2016), all of which are 
dysregulated in PD.  Secondly, the mechanism of α-synuclein-induced cell 
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death is highly debated. The Braak hypothesis (Braak et al., 2003; Braak et 
al., 2003b), which was widely accepted, suggested that α-synuclein 
pathology originates outside of the CNS, and once present in the gastro-
intestinal tract it can propagate in a prion-like manner along a vulnerable 
neuronal network to eventually reach the brain, where the proliferation and 
accumulation of α-synuclein into Lewy bodies causes degeneration of 
dopaminergic neurons. However, in recent years, a number of publications 
have precipitated a critical re-think of this hypothesis. Engelender and 
Isacson recently published their “Threshold Theory for Parkinson’s Disease” 
(Engelender and Isacson, 2017), where they suggest that α-synuclein 
pathology is present in both the central and enteric nervous systems at the 
same time, and that the time of onset of motor and NMS are different due 
to variances in neuronal vulnerability and the presence of extensive 
compensatory networks in the brain that are not present in peripheral 
neurons (Engelender and Isacson, 2017). Similarly, Benskey and colleagues 
(2016) put forward their ‘loss of function’ hypothesis, where they postulated 
that the accumulation of endogenous α-synuclein into LBs and LNs, and 
accompanying shift in subcellular localisation of α-synuclein from 
presynaptic terminals to cell soma, impedes the ability of α-synuclein to 
carry out its normal cellular functions and results in neuronal toxicity as seen 
in PD (Benskey et al., 2016). Thirdly, there is a growing body of evidence that 
indicates that the various clinical and pathological features of the 
synucleinopathies are increasingly dependent on the structure of the α-
synuclein that is present. In vitro studies have demonstrated the existence 
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of structurally different α-synuclein strains that display different levels of 
toxicity and seeding propensity (Bousset et al., 2013; Guo et al., 2013). This 
was built upon by Peelaerts and colleagues (2015), who fully characterised 
the distinct histopathological and behavioural phenotypes that are induced 
in vivo after administration of specific α-synuclein strains (Peelaerts et al., 
2015). Different strains of α-synuclein have been shown to trigger distinct 
inflammatory reactions (Gustot et al., 2015) and have also demonstrated 
species-specific effects (Abdelmotilib et al., 2017).  
Taken together, what is clear is that despite the overwhelming evidence that 
links α-synuclein to the pathophysiology of PD, there are vast gaps in our 
knowledge. Nonetheless, targeting α-synuclein as a potential therapy has 
shown promise and currently there are several different strategies that are 
being investigated, including immune targeting, reducing α-synuclein 
aggregation or synthesis, blocking the propagation of α-synuclein or 
enhancing the clearance and degradation of α-synuclein (reviewed by 
Olanow and Kordower, 2017 and Wong and Krainc, 2017). Of these, immune 
targeting is currently the most developed method, and a series of animal 
studies that used either active or passive immunisation of α-synuclein have 
repeatedly demonstrated significant reductions in α-synuclein-induced 
neurodegeneration and propagation as well as ameliorating motor deficits 
(Covell et al., 2017; Games et al., 2014; Spencer et al., 2017; Tran et al., 
2014). This has led very recently to the publication of data from the first-in-
human trial of PRX002, a monoclonal antibody targeting α-synuclein, which 
demonstrated not only that the drug has a favourable safety, tolerability and 
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pharmacokinetic profile but that it can reduce the amount of free serum α-
synuclein in a dose-dependent manner (Schenk et al., 2017). Future work is 
focusing on the completion of a double-blind placebo-controlled trial in 
patients with PD (Schenk et al., 2017).  
α-synuclein is also showing increasing potential as a biomarker. Levels of α-
synuclein in the cerebrospinal fluid (CSF) have repeatedly been shown to be 
elevated when compared to healthy age-matched controls (reviewed by 
Parnetti et al., 2013). More specifically, it appears that alterations in levels 
of the oligomeric form of α-synuclein in CSF are more sensitive (Aasly et al., 
2014; Tokuda et al., 2010) and has been used to differentiate between PDD 
and Alzheimer’s disease (Hansson et al., 2014). Recently, a combination of 
antibodies to detect both oligomeric and phosphorylated α-synuclein in CSF 
has been employed and been shown to successfully discriminate between 
PD patients and controls (Majbour et al., 2016b). Importantly, this 
combination of antibodies was also sufficiently sensitive to detect 
longitudinal changes in α-synuclein that reflect the progressive nature of PD 
(Majbour et al., 2016a). Nevertheless, lumbar punctures to collect CSF are 
invasive and high-risk procedures, and so alternative methods of biomarker 
detection would be highly worthwhile. Outside of the CNS, α-synuclein has 
been detected in the enteric nervous system (ENS) (Braak et al., 2006a), the 
olfactory mucosa (Duda et al., 1999), the submandibular gland (Adler et al., 
2016) and skin (Michell et al., 2005; Rodríguez-Leyva et al., 2014), although 
the evidence for using any of these as peripheral biomarkers remains 
controversial (reviewed by Malek et al., 2014 and Schneider et al., 2016).  
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In this thesis, we focused on the neuroprotective effects of voluntary 
exercise to ameliorate both motor and NMS of PD. Increasingly, lifestyle 
factors are being investigated for their relevance in decreasing the risk of 
developing PD, but also in the pathogenesis of the disease itself. Large-scale 
epidemiological studies have repeatedly shown that exercise can protect 
against the possibility of developing PD (Sasco et al., 1992; Shih et al., 2016; 
Yang et al., 2015). Moreover, acculumating evidence demonstrates that 
exercise can also alleviate both motor and NMS of PD (Cusso et al., 2016; 
LaHue et al., 2016). In this thesis, we showed that voluntary exercise 
ameliorated hippocampal-associated learning and memory tasks, and that 
this was likely mediated by modulation of adult hippocampal neurogenesis. 
The beneficial effects of exercise are thought to be mediated by a wide range 
of mechanisms, including enhanced hippocampal neurogenesis (reviewed 
by Ma et al., 2017), attenuation of neuroinflammation (reviewed by Ryan 
and Nolan, 2016), enhancement of antioxidant species (reviewed by 
Boccatonda et al., 2016 and de Sousa et al., 2017) and upregulation of the 
expression of neurotrophic factors (reviewed by Dinoff et al., 2016). 
Although neurotrophic factors such as GDNF and NRTN have shown some 
promising results in clinical trials (reviewed by Olanow et al., 2015), data 
from animal studies demonstrates that the trophic effects of GDNF are 
blocked by α-synuclein-induced downregulation of the transciption factor 
Nurr1 and it’s downstream receptor, Ret (M. Decressac et al., 2012). Given 
that in this thesis we show that exercise can ameliorate nigral degeneration 
as well as motor function in the AAV-α-synuclein model, further 
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investigation into alternative mechanisms of exercise-induced 
neuroprotection could provide new insight into novel downstream signalling 
pathways.   
 
7.1 Final conclusions 
In summary, this thesis demonstrates that the AAV-α-synuclein model is a 
reproducible and robust model of PD that can replicate both the motor 
symptoms and some of the primary NMS associated with the disease. 
Moreover, the model can be used to investigate potential therapeutic 
interventions such as voluntary exercise. There are currently no licensed 
medical therapies that alter the progression of the disease, and promising 
data from animal studies investigating neurotrophic factors and cell-based 
therapies did not translate to human clinical trials. Thus, an animal model 
that can replicate the primary features of PD could be used to screen 
potential drug compounds, contribute to knowledge needed to interrogate 
signalling mechanisms and enhance the translational impact of novel 


























This thesis has demonstrated that the AAV-α-synuclein rat model is a 
consistent and reliable animal model of PD that can be used to reproduce 
some of the NMS associated with the disease. Moreover, we show that 
overexpression of AAV-α-synuclein is a viable method to investigate 
potential therapeutic interventions such as voluntary exercise. These 
findings represent significant contributions to the present understanding of 
the neuroprotective effects of exercise, and give an insight into the cellular 
mechanisms behind these effects.  
One of the advantages of employing animal models of PD is the ability to 
comprehensively investigate cellular signalling and mechanisms that would 
be otherwise impossible in tissue from patients with PD. The discovery that 
overexpression of α-synuclein can block the trophic effects of GDNF (M. 
Decressac et al., 2012) may go some way to explaining the inconsistent 
results observed in clinical trials of neurotrophic factors (Olanow et al., 
2015), and highlights the critical importance of using a viable and 
representative animal model of PD in pre-clinical research. In this thesis, we 
show that despite overexpression of α-synuclein, voluntary running can 
significantly improve dopaminergic survival and performance on 
hippocampal-associated tasks, which is at least partly due to enhancing adult 
hippocampal neurogenesis. However, further work is required to fully 
elucidate the neuroprotective effects of voluntary running in this study. The 
neurotrophic factor GDF-5 has been shown in vitro to mediate its trophic 
effects through a different signalling pathway compared to other NTFs 
(Hegarty et al., 2013) and recently an in vivo study further demonstrated its 
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ability to protect hippocampal neurons against toxic insult (Zhao et al., 
2017). However, the interplay between GDF-5 and α-synuclein, and other 
neuropromoting agents, has yet to be investigated.  
Overexpression of α-synuclein has been demonstrated to induce a robust 
neuro-inflammatory reaction (Alvarez-Erviti et al., 2011; Wilms et al., 2009), 
and the propagation of α-synuclein throughout the brain may be in part due 
to deficits in microglial activity (Bliederhaeuser et al., 2015). Given that 
exercise is  known to attenuate neuroinflammation (reviewed by Ryan and 
Nolan, 2016; Spielman et al., 2016), it is also possible that some of the 
neuroprotective effects seen in this thesis could be due to modulation of 
microglial responses, and this could be a future direction for this work.  
From a more clinical perspective, there are a number of outstanding 
questions that remain unanswered, both specific to the relationship 
between α-synuclein and PD, and also about PD itself. Deweerdt recently 
listed the four big questions about PD (Deweerdt, 2016), namely 1) how does 
PD begin; 2) what is the role of α-synuclein in PD; 3) what is the role of the 
gut in PD and 4) what is the best way to divide people with the disease into 
subtypes.  
Taken together, it is clear that for any major therapeutic advances in PD, a 
viable, robust and reproducible animal model is necessary to 
comprehensively identify molecular, cellular and behavioural contributions, 
which in turn will serve to optimise and enhance the translational impact of 
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